A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent by Mant, D et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 21 ISSUE 32 MAY 2017
ISSN 1366-5278
DOI 10.3310/hta21320
A randomised controlled trial to assess the 
cost-effectiveness of intensive versus no scheduled 
follow-up in patients who have undergone resection 
for colorectal cancer with curative intent
David Mant, Alastair Gray, Siân Pugh, Helen Campbell,  
Stephen George, Alice Fuller, Bethany Shinkins,  
Andrea Corkhill, Jane Mellor, Elizabeth Dixon, Louisa Little,  
Rafael Perera-Salazar and John Primrose

A randomised controlled trial to assess the
cost-effectiveness of intensive versus no
scheduled follow-up in patients who have
undergone resection for colorectal cancer
with curative intent
David Mant,1 Alastair Gray,2 Siân Pugh,3
Helen Campbell,2 Stephen George,4 Alice Fuller,1
Bethany Shinkins,5 Andrea Corkhill,6 Jane Mellor,6
Elizabeth Dixon,6 Louisa Little,6 Rafael Perera-Salazar1
and John Primrose3*
1Nuffield Department of Primary Care Health Sciences, University of Oxford,
Oxford, UK
2Nuffield Department of Population Health, University of Oxford, Oxford, UK
3University Surgery, University of Southampton, Southampton, UK
4Faculty of Medicine, University of Southampton, Southampton, UK
5Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
6Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
*Corresponding author
Declared competing interests of authors: none
Published May 2017
DOI: 10.3310/hta21320
This report should be referenced as follows:
Mant D, Gray A, Pugh S, Campbell H, George S, Fuller A, et al. A randomised controlled trial to
assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have
undergone resection for colorectal cancer with curative intent. Health Technol Assess 2017;21(32).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.058
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 99/10/99. The contractual start date
was in April 2004. The draft report began editorial review in January 2016 and was accepted for publication in January 2017. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mant et al. under the terms of a commissioning
contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and
study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement
is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre,
Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief
Health Technology Assessment 
NIHR Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: journals.library@nihr.ac.uk
Editor-in-Chief
Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the
Centre of Evidence-Based Dermatology, University of Nottingham, UK
Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK
Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School,
University of Warwick, UK
Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research Group, 
University of Winchester, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
A randomised controlled trial to assess the cost-effectiveness
of intensive versus no scheduled follow-up in patients who
have undergone resection for colorectal cancer with
curative intent
David Mant,1 Alastair Gray,2 Siân Pugh,3 Helen Campbell,2
Stephen George,4 Alice Fuller,1 Bethany Shinkins,5 Andrea Corkhill,6
Jane Mellor,6 Elizabeth Dixon,6 Louisa Little,6 Rafael Perera-Salazar1
and John Primrose3*
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
2Nuffield Department of Population Health, University of Oxford, Oxford, UK
3University Surgery, University of Southampton, Southampton, UK
4Faculty of Medicine, University of Southampton, Southampton, UK
5Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
6Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
*Corresponding author J.N.Primrose@soton.ac.uk
Background: Intensive follow-up after surgery for colorectal cancer is common practice but lacks a firm
evidence base.
Objective: To assess whether or not augmenting symptomatic follow-up in primary care with two
intensive methods of follow-up [monitoring of blood carcinoembryonic antigen (CEA) levels and scheduled
imaging] is effective and cost-effective in detecting the recurrence of colorectal cancer treatable surgically
with curative intent.
Design: Randomised controlled open-label trial. Participants were randomly assigned to one of four
groups: (1) minimum follow-up (n = 301), (2) CEA testing only (n = 300), (3) computerised tomography
(CT) only (n = 299) or (4) CEA testing and CT (n = 302). Blood CEA was measured every 3 months for
2 years and then every 6 months for 3 years; CT scans of the chest, abdomen and pelvis were performed
every 6 months for 2 years and then annually for 3 years. Those in the minimum and CEA testing-only
arms had a single CT scan at 12–18 months. The groups were minimised on adjuvant chemotherapy,
gender and age group (three strata).
Setting: Thirty-nine NHS hospitals in England with access to high-volume services offering surgical
treatment of metastatic recurrence.
Participants: A total of 1202 participants who had undergone curative treatment for Dukes’ stage A to C
colorectal cancer with no residual disease. Adjuvant treatment was completed if indicated. There was no
evidence of metastatic disease on axial imaging and the post-operative blood CEA level was ≤ 10 µg/l.
Main outcome measures: Primary outcome Surgical treatment of recurrence with curative intent.
Secondary outcomes Time to detection of recurrence, survival after treatment of recurrence, overall
survival and quality-adjusted life-years (QALYs) gained.
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Results: Detection of recurrence During 5 years of scheduled follow-up, cancer recurrence was detected
in 203 (16.9%) participants. The proportion of participants with recurrence surgically treated with curative
intent was 6.3% (76/1202), with little difference according to Dukes’ staging (stage A, 5.1%; stage B,
7.4%; stage C, 5.6%; p = 0.56). The proportion was two to three times higher in each of the three more
intensive arms (7.5% overall) than in the minimum follow-up arm (2.7%) (difference 4.8%; p = 0.003).
Surgical treatment of recurrence with curative intent was 2.7% (8/301) in the minimum follow-up group,
6.3% (19/300) in the CEA testing group, 9.4% (28/299) in the CT group and 7.0% (21/302) in the CEA
testing and CT group. Surgical treatment of recurrence with curative intent was two to three times higher
in each of the three more intensive follow-up groups than in the minimum follow-up group; adjusted
odds ratios (ORs) compared with minimum follow-up were as follows: CEA testing group, OR 2.40, 95%
confidence interval (CI) 1.02 to 5.65; CT group, OR 3.69, 95% CI 1.63 to 8.38; and CEA testing and CT
group, OR 2.78, 95% CI 1.19 to 6.49. Survival A Kaplan–Meier survival analysis confirmed no significant
difference between arms (log-rank p = 0.45). The baseline-adjusted Cox proportional hazards ratio
comparing the minimum and intensive arms was 0.87 (95% CI 0.67 to 1.15). These CIs suggest a
maximum survival benefit from intensive follow-up of 3.8%. Cost-effectiveness The incremental cost
per patient treated surgically with curative intent compared with minimum follow-up was £40,131 with
CEA testing, £43,392 with CT and £85,151 with CEA testing and CT. The lack of differential impact on
survival resulted in little difference in QALYs saved between arms. The additional cost per QALY gained of
moving from minimum follow-up to CEA testing was £25,951 and for CT was £246,107. When compared
with minimum follow-up, combined CEA testing and CT was more costly and generated fewer QALYs,
resulting in a negative incremental cost-effectiveness ratio (–£208,347) and a dominated policy.
Limitations: Although this is the largest trial undertaken at the time of writing, it has insufficient power to
assess whether or not the improvement in detecting treatable recurrence achieved by intensive follow-up
leads to a reduction in overall mortality.
Conclusions: Rigorous staging to detect residual disease is important before embarking on follow-up.
The benefit of intensive follow-up in detecting surgically treatable recurrence is independent of stage. The
survival benefit from intensive follow-up is unlikely to exceed 4% in absolute terms and harm cannot be
absolutely excluded. A longer time horizon is required to ascertain whether or not intensive follow-up is an
efficient use of scarce health-care resources. Translational analyses are under way, utilising tumour tissue
collected from Follow-up After Colorectal Surgery trial participants, with the aim of identifying potentially
prognostic biomarkers that may guide follow-up in the future.
Trial registration: Current Controlled Trials ISRCTN41458548.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 32.
See the NIHR Journals Library website for further project information.
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Plain English summary
Bowel cancer is the second most common cause of cancer death in the UK. When the cancer isconfined to the bowel and/or surrounding lymph nodes (early bowel cancer), it can often be treated
with an operation. Following surgery, many patients will be cured; however, for others, the cancer may
come back (recur) either locally in the bowel or in another organ such as the liver. Consequently, after
surgery for early bowel cancer, clinicians often follow up patients in the hope of detecting any recurrent
cancer at an early and treatable stage. The way in which patients are followed up is variable. Some
patients have regular computerised tomography (CT; detailed radiography) scans and/or blood tests to look
for signs of cancer. Others are simply advised to report any concerning symptoms.
The FACS (Follow-up After Colorectal Surgery) trial was undertaken to determine the most effective form
of follow-up. Patients were allocated to one of four follow-up regimens: (1) minimal follow-up with a
single CT scan, (2) regular CT scans, (3) regular blood tests with a single CT scan or (4) both regular CT
scans and blood tests. The results demonstrate that regular follow-up with either CT scans or blood tests is
better than minimal follow-up at detecting recurrent cancer at a treatable stage. There was no benefit of
having both CT scans and blood tests. Of the intensive follow-up strategies, regular blood tests with a
single CT scan appears to be both economical and well accepted by patients.
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Scientific summary
Background
The original protocol for the FACS (Follow-up After Colorectal Surgery) trial specified the main outcome
as overall mortality based on 1200 patients randomised to each intervention arm and followed up for
5 years. It was planned to recruit 2400 participants in each factorial group (4800 total) to detect a 4%
improvement from 49% to 53% in each factorial comparison [carcinoembryonic antigen (CEA) testing vs.
no CEA testing, computerised tomography (CT) vs. no CT]. Difficulties in recruitment were encountered
from the outset. Despite a major expansion in the number of centres recruiting and a substantial protocol
amendment to reflect changing clinical views on the position of equipoise (a single CT scan at the
investigator’s discretion 12–18 months post randomisation was added to the follow-up schedule for the
minimum follow-up arm), many clinicians and patients had concerns regarding participation. In addition,
it was noted that the overall mortality was much lower than expected. On this basis, after interim review
of 500 participants, the Data Monitoring and Ethics Committee (DMEC) advised that the sample size be
reduced to 1180 in total and that the primary outcome be changed to ‘surgical treatment of recurrence
with curative intent’. Finally, owing to a significant interaction, the primary analysis was altered from
factorial to a three-way comparison between each of the three intensively monitored groups and the
group with no additional monitoring (apart from a single CT scan).
The Health Technology Assessment programme accepted this proposal for a surrogate end point and
recruitment was stopped in July 2009, when just over 1200 participants had entered the trial. In August
2012, when all participants had completed 3 years of scheduled follow-up, the randomisation code was
broken at the recommendation of the DMEC and an interim analysis was conducted. This analysis showed
that intensive follow-up increased, by approximately threefold, the number of patients with recurrence
who could be treated surgically with curative intent, but there was no significant difference in overall
survival. The further analysis reported here is based on data collected up to the end of November 2014,
when all surviving participants had completed the scheduled 5 years of follow-up and the median time
elapsed since the recruitment of each participant was 8.7 years (range 5.5 to 11.9 years). The one
exception is the observational analysis of recurrence, which is based on the data available at the time
of the interim analysis.
Aim and objectives
Aim
To assess whether or not augmenting symptomatic follow-up in primary care with two intensive methods
of follow-up (monitoring of blood CEA levels in primary care and scheduled imaging in hospital) is clinically
effective and cost-effective in detecting the recurrence of colorectal cancer treatable surgically with
curative intent and in improving survival.
Specific objectives
1. To estimate the effect of 3- to 6-monthly measurement of blood CEA levels and 6- to 12-monthly CT
imaging plus an additional colonoscopy on:
i. the number and cost of detecting recurrences treatable surgically with curative intent
ii. overall and colorectal cancer-specific mortality
iii. cost per quality-adjusted life-year (QALY) saved.
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2. To describe in trial participants:
i. the frequency and pattern of recurrence by site and stage of the primary tumour
ii. the length of post-recurrence survival by treatment intent
iii. the cost of NHS services utilised
iv. health-related quality of life (HRQoL) during follow-up.
Methods
Design
A randomised controlled trial with a 2 × 2 factorial design; participants were randomised independently to
(1) CT imaging every 6–12 months or at minimum follow-up and (2) blood testing to measure CEA levels
every 3–6 months or at minimum follow-up.
Participants
The trial was conducted in 39 NHS hospitals in England that had access to high-volume regional services
geared towards offering surgical treatment for metastatic recurrence. The participants were recruited
between January 2003 and August 2009. All of the participants had undergone curative treatment for
primary colorectal cancer with no residual disease, microscopically clear margins and Dukes’ A to C stage
(tumour, node, metastasis stage I–III). Patients were excluded if they had concurrent serious illness,
dominantly inherited colon cancer or an inability to give written informed consent or if they were involved
in a primary treatment trial with conflicting follow-up requirements.
Interventions
Follow-up was scheduled for 5 years from trial entry. Patients received one of four types of follow-up:
(1) CEA testing follow-up – 3-monthly measurement of blood CEA for 2 years and then 6-monthly
measurement for 3 years, with a single chest, abdominal and pelvic CT scan at 12–18 months; (2) CT
follow-up – chest, abdominal and pelvic CT scan 6-monthly for 2 years and then annually for 3 years;
(3) CEA testing and CT follow-up – both blood CEA measurement and CT imaging as above; and
(4) minimum follow-up – no scheduled follow-up except a single chest, abdominal and pelvic CT scan
at 12–18 months if requested at study entry by the hospital clinician (187, 62% received a CT scan). All
patients were offered an end-of-trial colonoscopy at 5 years; in the two CT arms, a colonoscopy to check
for luminal recurrence or metachronous primary cancer was also undertaken at 2 years.
Primary clinical outcome
Surgical treatment of identified recurrence with curative intent. Data on treatment of recurrence and
treatment intent were recorded on case report forms (CRFs) by local National Cancer Research Network
staff (who had access to the full clinical records).
Secondary clinical outcomes
(1) Overall survival, (2) deaths from colorectal cancer, (3) time to detection of recurrence and
(4) post-recurrence survival. Information on deaths was collected by flagging each participant at the
Office for National Statistics (ONS) central registry; cause of death was abstracted from death certificates.
Economic outcomes
The discounted total number of QALYs gained over the 5 years of follow-up was the primary outcome
measure for the cost-effectiveness analysis. The secondary outcomes were (1) resource use, (2) NHS costs
and (3) HRQoL. QALYs were calculated by applying the average index score of HRQoL to the observed
survival in each year.
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Sample size
To detect a 6% absolute difference in the primary outcome between minimum follow-up and any of the
three other more intensive follow-up arms with 80% power (two-sided alpha 0.05) was estimated to
require 205 patients in each of the four follow-up arms; 590 subjects allocated to each factorial group
(CEA measurement and CT imaging) were estimated to provide 80% power to detect a 3% absolute
difference in the factorial comparison. We therefore planned to stop recruitment when we reached a
minimum of 1180 participants.
Randomisation
Patients were independently allocated at random on a 1 : 1 ratio to receive or not receive each of the
factorial interventions (CEA measurement and hospital-based imaging) using the telephone randomisation
service provided by the Oxford Clinical Trials Unit. A computerised algorithm was applied using the
method of minimisation to balance patient characteristics within each centre; the balancing variables were
adjuvant chemotherapy, gender and age group (three strata).
Statistical methods for clinical analyses
When feasible, crude data are presented with statistical comparison made between randomisation arms
based on chi-squared tests for binary or categorical data, the t-test or analysis of variance as appropriate
for comparing group means and the Kruskal–Wallis test for comparing medians. Time to recurrence was
analysed by the Kaplan–Meier method, to take account of both time-censoring and the difference in the
number of recurrences detected in each arm. The plots of time to recurrence are compared by the log-rank
Mantel–Cox statistic. Adjusted odds ratios (ORs) for the main outcome were calculated by binary logistic
regression; Cox HRs are also reported for comparison of overall mortality. The primary analysis was
undertaken using IBM Statistical Product and Service Solutions (SPSS) version 20 (IBM Corporation,
Armonk, NY, USA).
Statistical methods for economic analyses
The analysis was conducted from the perspective of the UK NHS, with national average unit costs
(expressed in 2012–13 UK pounds sterling) obtained from a variety of sources and applied to patient-level
resource-use volumes to derive costs per patient. As the time horizon for the analysis was 5 years, costs
and QALYs were discounted to present values at an annual rate of 3.5%. Multiple imputation using
chained regression equations were used to impute missing values. An incremental cost-effectiveness ratio
(ICER) was computed and compared against the cost-effectiveness threshold specified by the National
Institute for Health and Care Excellence (£20,000–30,000 per QALY). Non-parametric bootstrapping was
used to generate cost-effectiveness acceptability curves. All economic analyses were performed using
Stata® version 12 (StataCorp LP, College Station, TX, USA).
Protocol adherence and withdrawal
Adherence to protocol was ascertained through NHS hospital and laboratory records. A secondary
per-protocol analysis is reported that excludes the 308 patients who received any unscheduled
investigation or had missed more than one scheduled examination. Reasons for withdrawal were sought.
All patients who withdrew gave their consent for continued follow-up through ONS mortality records. The
analysis of other clinical outcomes (including recurrence and recurrence treated surgically with curative
intent) is censored on the date of withdrawal.
Clinical results
Detection of recurrence
During the 5 years of scheduled follow-up, cancer recurrence was detected in 203 (16.9%) participants.
Two-thirds of recurrences (134, 66.0%) were detected by a scheduled follow-up investigation: 88 (64.7%)
by CT, 43 (31.6%) by CEA testing and five at colonoscopy (either by colonoscopy or by another investigation
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initiated at the consultation) (2.98%). Fewer recurrences were detected in the minimum arm than in the
intensive follow-up arms (12.6% vs. 18.3%; p = 0.02).
Recurrence treatable with curative intent
The proportion of participants with recurrence surgically treated with curative intent was 6.3% (76/1202)
overall, with little difference according to Dukes’ staging (stage A, 5.1%; stage B, 7.4%; stage C, 5.6%;
p = 0.56). The proportion was two to three times higher in each of the three more intensive follow-up
arms (7.5% overall) than in the minimum follow-up arm (2.7%) (absolute difference 4.8%; p = 0.003).
The adjusted OR in the factorial comparison was 2.5 for CEA testing only (p = 0.04) and 3.7 for CT only
(p = 0.002). There was no evidence of any additive effect (the adjusted OR for the combined CT and CEA
testing arm was not significantly different from that for CT or CEA testing alone).
Post-recurrence survival
The number of patients with recurrence detected during scheduled follow-up who were still alive at the
time of analysis was higher in intensive follow-up arms (4.8% vs. 2.3%; p = 0.07), as was the median
post-recurrence survival (27.3 vs. 14.6 months; p = 0.11), but neither difference is statistically significant.
Of the patients with recurrence treated with curative intent, 53% were alive at the end of follow-up.
Overall survival
Total mortality at a median of 8.7 years post randomisation in each group was as follows: CEA testing,
63 deaths (33%); CT, 80 deaths (32%); CEA testing and CT, 63 deaths (27%); and minimum follow-up,
52 deaths (28%). There were no significant differences in the total number of deaths, or in the number of
deaths attributed to colorectal cancer, between the four randomisation arms or two factorial groups. The
Kaplan–Meier overall survival analysis showed no significant difference in survival over time between arms
(log-rank p = 0.45). The baseline-adjusted Cox hazard ratio (HR) comparing the minimum and intensive
arms showed a non-significant survival advantage for minimum follow-up of 0.87 [95% confidence
interval (CI) 0.67 to 1.15]. These CIs suggest an upper limit to the absolute mortality benefit from intensive
follow-up of 3.8%; the lower limit means that it is impossible to exclude the possibility of harm, although
this is unlikely to be based on the survival of patients treated with curative intent.
Observational analysis of recurrence by site
This analysis was based on 189 patients with recurrence in the 2012 data set. The incidence of recurrence
varied according to the site of the primary (right colon, 51/379, 14%; left colon, 68/421, 16%; rectum,
70/332, 21%; p = 0.023) and initial stage (Dukes’ A, 26/249, 10%; Dukes’ B, 81/537, 15%; Dukes’ C,
82/346, 24%; p < 0.0001). Recurrences from lower-stage cancers were more likely to be treatable with
curative intent (Dukes’ A, 13/26, 50%; Dukes’ B, 32/81, 40%; Dukes’ C, 20/82, 24%; p = 0.03). Those
with rectal cancers benefited most from follow-up (proportion with treatable recurrence: rectum, 30/332,
9%; left colon, 23/421, 6%; right colon, 12/379, 3%; p = 0.003). Both initial stage (log-rank p = 0.005)
and site of primary cancer (log-rank p = 0.01) influenced post-recurrence survival.
Economic results
The incremental cost per patient treated surgically with curative intent compared with minimum follow-up
was £40,131 with CEA testing, £43,392 with CT and £85,151 with CEA testing and CT. However, the
lack of differential impact on survival means there was little difference in QALYs saved between the
minimum follow-up [3.61, standard error (SE) 0.07] and intensive arms (CEA testing 3.66, SE 0.06; CT
3.62, SE 0.07; CEA testing and CT 3.59, SE 0.07). Consequently, the overall mean (SE) patient costs per
QALY saved were lower in the minimum follow-up arm [£3138 (£334)] than in the more intensive arms
[£4613 (£438) CEA testing; £6048 (£393) CT; £6796 (£618) CEA testing and CT]. The additional cost per
QALY gained of moving from minimum follow-up to CEA testing was £25,951 and for CT was £246,107.
When compared with minimum follow-up, combined CEA testing and CT was more costly and generated
fewer QALYs resulting in a negative ICER (–£208,347) and a dominated policy.
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Conclusion
The proportion of participants with recurrence treated with curative intent was lower than predicted from
previous trials (6.0% overall), but it was three times higher in the more intensive follow-up arms than in
the minimum follow-up arm. Both CEA testing (with a single CT scan) and regular CT imaging are effective
modes of follow-up, but combining regular CEA testing and CT imaging provided no additional benefit.
There was no statistical difference in overall deaths or colorectal cancer deaths in the minimum compared
with the intensive follow-up arms after a median of 8.7 years of observation. The CIs around the HR show
that if there is a survival benefit from intensive follow-up in the first 10 years it is very unlikely to exceed
4% in absolute terms and harm cannot be excluded. Of the intensive follow-up strategies, CEA testing has
the lowest cost per treatable recurrence detected and the lowest cost per QALY gained when compared
with minimum follow-up. However, a longer time horizon is required to ascertain whether or not
identifying more curatively treatable recurrences offers a survival benefit and thus a more efficient use of
scarce health-care resources than minimum follow-up.
Trial registration
This trial is registered as ISRCTN41458548.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Colorectal cancer is a major health problem. In the UK, around 32,000 cases are diagnosed annually and
16,000 deaths are attributed to the disease.1 Surgery is the mainstay of treatment and most cases cured
are cured by surgery alone. Adjuvant chemotherapy reduces the risk of relapse in high-risk patients and
radiotherapy reduces the local recurrence rate in patients with high-risk rectal cancer. For selected patients
who develop either local recurrence or distant metastases following surgery for primary disease, resection
of recurrent disease, most commonly in the liver, may still result in cure. In a meta-analysis of > 20,000
patients, 40% of patients having liver resection were alive after 5 years and 30% were alive at 10 years.2
Similar, if less well-documented, results are seen in surgery for local recurrence or lung metastases.3,4 In
those not considered to have upfront resectable recurrent disease, the early initiation of chemotherapy
may prolong survival5 or, importantly, may downsize metastases to operability.6
Traditionally, patients who have curative surgery for colorectal cancer are subject to long-term follow-up,
the detection of treatable recurrence being one of the objectives. Curatively treated cancer in this setting
is commonly held to refer to a patient without metastatic disease other than in local lymph nodes in
whom all disease has been removed. Clinicians use various protocols, but few, if any, are evidence
based. The costs to the NHS of follow-up are substantial and they need to be justified by evidence of
cost-effectiveness. Although a number of studies have assessed the value of follow-up of patients with
curatively resected colorectal cancer, none provides a definitive answer, for a variety of reasons.
At the time this study was developed, a number of randomised trials of colorectal cancer follow-up had
been published.7–10 The largest of these7 showed no benefit of follow-up, but the protocol did not include
intensive imaging. Two small and underpowered studies appeared to show benefit of follow-up, but these
did not achieve statistical significance.8,9 Only one of these trials8 included intensive liver imaging. A study10
of 325 patients compared intensive follow-up with computerised tomography (CT) and colonoscopy, with
a structured clinical review and simple tests. More patients with asymptomatic metastases were detected in
the investigational arm, but the number of potentially curative hepatectomies was not different. However,
this study may not have been powerful enough to detect a difference between the two active follow-up
schedules.
Preliminary results of a further trial to evaluate the effect of undertaking ‘second-look’ surgery in response
to a rise in carcinoembryonic antigen (CEA) during follow-up were reported in 1984.11 At the time that the
Follow-up After Colorectal Surgery (FACS) trial was designed, this trial had not demonstrated any benefit
from the intervention, and a subsequent publication confirmed this.12 However, the trial suffers from the
criticism that patients who developed recurrence were not commonly offered treatments that could impact
on survival, such as liver/lung resection. Of the non-randomised trials, a meta-analysis suggested benefit if
the follow-up strategy included CEA testing.13 A Cochrane review concluded that there may be a benefit
of imaging follow-up (around 8%), but that further adequately powered studies were necessary14 as
publication bias was likely.
It is recognised that most of the trials performed in this area preceded the common use of liver resection
and modern effective chemotherapy in patients found to have metastatic disease. However, there is
sufficient clinical and scientific uncertainty about a potentially important clinical treatment to justify a trial
on ethical grounds. A pre-trial economic model was devised to assist in the development of the trial
protocol and was used to assess the probable costs, effects and cost-effectiveness of each of the trial
options. The results of this modelling (shown in Appendix 1 along with the parameter values) indicated
that relatively small gains in survival could well be cost-effective, that it was important to include a primary
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care-based follow-up option with CEA monitoring in the study, that accurate information was required on
palliative care alongside other aspects of resource use and that the cost-effectiveness results would be
strongly influenced by the duration of follow-up and analytic horizon.
Four objectives of follow-up were considered in developing the trial.
1. Early detection of metastatic disease. There is unambiguous evidence that the resection of colorectal
liver metastases may result in cure. Approximately 40% of patients who have a R0 (≥ 1-mm clearance
at lateral margins) resection performed (no residual disease, microscopically clear margins) will survive
for 5 years and 30% will survive to 10 years.2,15 Recurrence after 10 years is not reported. The data for
lung metastases are similar, although somewhat more contentious.3,16 Although it is not absolutely
certain how many patients with liver metastases are suitable for resectional surgery, the only
prospective analysis suggests that the figure may be as high as 20%.17 There is also some evidence of a
survival benefit (beyond lead time) from early diagnosis and pre-symptomatic treatment with cytotoxic
chemotherapy in patients not suitable for resection.5 Furthermore, cytotoxic chemotherapy increases in
a number of patients suitable for resectional liver surgery18 and also improves the outlook of those with
resectable disease.19
2. Removal of further adenomatous polyps and metachronous cancer. Patients who have developed
colorectal cancer are at increased risk of further adenomatous polyps and metachronous cancer. The
detection and removal of metachronous polyps or early cancer may benefit the patient in survival terms.
However, it is held that if a ‘clean colon’ (no polyps) is achieved during initial treatment, then follow-up
colonoscopy after several years is adequate for patients without specific genetic susceptibility.20
3. Early detection of surgically treatable luminal recurrence. Endoscopy may detect luminal recurrence.
However, luminal recurrence is uncommon21 and can be a manifestation of more extensive local
recurrence. At the time of trial design, there was uncertainty regarding whether or not this is
commonly curable.22
4. Improvement in quality of life. One randomised study suggested that follow-up has a small
quality-of-life advantage over no follow-up.23 However, a randomised trial of hospital- and community-
based follow-up of patients with breast cancer in the UK, comparing quality of life and diagnostic delay,
showed no advantage of hospital follow-up and found that patient satisfaction with care was higher in
the general practice arm.24
Audit evidence suggests that follow-up, as normally practised in the early 2000s, when the trial was
designed, seldom included surveillance with tumour markers or regular imaging.25 Such practice was
unlikely to achieve any of the four ends detailed above. Clinical examination may provide reassurance,
but clinical examination is not clear that this reassurance is best provided in a hospital setting and it is
unlikely to detect many cases of treatable recurrence. The use of colonoscopy in the detection of
metachronous polyps is also established,26 and will ultimately impact on the incidence of metachronous
cancer,20 but this need not be frequent. Anastomotic and missed synchronous cancer may also be detected
(in spite of apparently complete colonic imaging), but the detection rate is low.21 The follow-up modalities
most likely to influence the primary end point were intensive imaging and serial tumour marker
measurements. There was evidence that these could detect recurrence at an early and treatable stage.14
At the time of developing the trial, spiral CT imaging was probably the best non-invasive, widely available
method of detecting colorectal metastases. Even so, the sensitivity reported varied between approximately
75% and 94%,27,28 depending on the gold standard used. Spiral CT imaging is expensive and involves a
considerable ionising radiation dose. Magnetic resonance imaging (MRI) does not involve ionising radiation
and is more sensitive for detecting liver metastases (around 80%),27 but it is much less effective for the
detection of lung and other metastases, is more expensive and is less widely available. Transabdominal
ultrasound is widely available and inexpensive, but it is less sensitive for the detection of hepatic
metastases (77%)28 and generally unhelpful in the detection of most extrahepatic metastases. Six-monthly
CT is affordable in service terms and is currently used, with variable frequency, in most colorectal
cancer units.
INTRODUCTION
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In order to satisfy Ionising Radiation (Medical Exposure) Regulations 2000 regulations,29 and to reflect the
findings published in Radiation Protection Dosimetry,30 the patient information sheet indicated probable
radiation doses and the cancer risk associated with CT imaging during the study. The patients randomised
to the CT and CEA testing plus CT arms who completed all seven CT scans were exposed to a total
effective radiation dose of about 140 mSv, associated with a lifetime risk of induction of a fatal cancer
of about 1 in 2000. For the small group of younger (aged < 70 years) participants, the risk is higher,
approximately 1 in 300. Risk from a particular radiation dose increases with younger age because there is
more time for any genetic damage caused by the radiation to progress to a clinical problem.
The International Commission on Radiological Protection report on ‘Radiological Protection in Biomedical
Research’ categorises the level of radiation involved in this study as ‘moderate’, with a ‘substantial’
societal benefit expected.31 If a participating centre was unable to comply with these dose constraints, the
co-ordinating centre (Southampton) would be informed. A local amendment of the patient information
sheet would then be produced and submitted for approval by the main Research Ethics Committee
(South West Multi-centre Research Ethics Committee).
Although a number of tumour markers are expressed in patients with colorectal cancer, CEA levels are
most frequently detected.32 It has been shown to be a useful adjunct to the detection of recurrent disease
in colorectal cancer32 and can be used to monitor the progress of patients undergoing chemotherapy
for colorectal cancer.33 CEA monitoring is risk free and has the advantage of being able to be used in
primary care. At the time the protocol was developed, an elevated CEA level was thought to have a 77%
sensitivity for recurrence (100% for liver metastases) combined with a 98% specificity,27 although a
recently published Cochrane review suggests poorer diagnostic performance.34 The elevation in CEA level
usually occurs prior to progression appearing on imaging.33
In the context of the radically different follow-up modalities that were being proposed, we considered that
assessment of quality of life was essential. The EuroQol-5 Dimensions (EQ-5D) is a generic measure that
assesses five broad dimensions of health status: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression.35 The EQ-5D also provides utility scores for use in cost–utility analyses. The European
Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (quality of life) is a disease-specific
instrument widely used in European oncology trials that provides assessments of physical function, role
function, cognitive function, emotional function, social function, symptoms and a global judgement of
quality of life.36 The Hospital Anxiety and Depression Scale (HADS) is also widely used in oncology trials,
providing assessments of two dimensions of psychological well-being, anxiety and depression, with items
that avoid physical symptoms that may arise from physical, rather than psychological, health.37 Acceptability
of follow-up regimes would then be assessed by a modified form of a College of Health Questionnaire that
has proved sensitive to differences in follow-up regimes in patients with breast cancer.38 The instrument
addresses patients’ perceptions of three aspects of health care: service delivery, consultations and
continuity. A small number of items were also selected and piloted from the seven-item questionnaire used
by Kjeldsen et al.23 in their study of follow-up after radical colorectal surgery. These items more directly
address issues of the perceived value and distress of follow-up visits for patients after colorectal surgery.
Health-related quality-of-life (HRQoL) instruments (EQ-5D, EORTC QLQ-C30, HADS) were selected
because they have been validated for use in oncology trials; their content is appropriate to assess the
impact of follow-up regimes and the number of items (49) should impose a relatively modest burden on
respondents. Two more condition-specific instruments were published at the time of writing the FACS trial
protocol assessing HRQoL for colorectal cancer, but they were not considered to address any important
issues ignored by the selected battery of instruments and did not appear to be developed to address
problems experienced by patients during the period following surgery.39,40
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Objective
The study objective was to assess the effect on the number of recurrences treated surgically with curative
intent of augmenting symptomatic follow-up in primary care with two intensive methods of follow-up:
monitoring of a tumour marker in primary care and intensive imaging in hospital.
INTRODUCTION
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Chapter 2 Methods
Trial design
This was a factorial 2 × 2 pragmatic randomised controlled trial to assess the outcome of scheduled follow-up
following primary curative treatment of colorectal cancer with blood CEA testing and/or CT imaging (plus
additional colonoscopy) for 5 years, compared with minimal symptomatic follow-up. Participants were
randomised independently (on a 1 : 1 allocation ratio) to 6- to 12-monthly CT imaging or minimum follow-up
and to 3- to 6-monthly CEA testing or minimum follow-up. The minimum and CEA testing arms were
permitted a single CT scan at 12–18 months.
Participants
The trial was conducted in 39 NHS hospitals in England that had access to high-volume regional services
geared towards offering surgical treatment for metastatic recurrence. Participants were recruited between
January 2003 and August 2009. All participants had undergone curative treatment for primary colorectal
cancer with no residual disease, microscopically clear margins and Dukes’ A to C stage [tumour, node,
metastasis (TNM) stage I–III]. They were disease free on colonic imaging with no evidence of metastatic
disease (confirmed by CT or MRI liver scan and chest CT scan) and with a post-operative blood CEA level
of ≤ 10 µg/l. For patients having adjuvant therapy, CEA level was measured after the completion of
chemotherapy and a CT scan was performed.
For a patient to enter the trial, their primary curative treatment had to be complete. Patients were
excluded if they had concurrent serious illness, dominantly inherited colon cancer or an inability to give
written informed consent or if they were involved in a primary treatment trial with conflicting follow-up
requirements. Potential participants who were aged < 50 years or were > 6 months from completion of
primary or adjuvant treatment were included only if a case for their inclusion was agreed by the chief
surgical investigator.
Interventions
Follow-up was scheduled for 5 years from trial entry. The factorial design, with independent allocation to
the CEA testing and CT interventions, meant that patients received one of four types of follow-up:
1. CEA testing follow-up – 3-monthly measurement of blood CEA level for 2 years, and then 6-monthly
for 3 years, with a single chest, abdominal and pelvic CT scan at 12–18 months
2. CT follow-up – 6-monthly chest, abdominal and pelvic CT scan for 2 years, and then annually for
3 years
3. CEA testing and CT follow-up – both blood CEA measurement and CT imaging as above
4. minimum follow-up – no scheduled follow-up except a single chest, abdominal and pelvic CT scan at
12–18 months if requested at study entry by the hospital clinician.
The discretional CT scan in the minimum arm was adopted as a protocol amendment in May 2005 to
reflect changing clinical opinion among many participating clinicians on the position of equipoise following
publication of new national guidance on follow-up.41
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All patients had been investigated by colonoscopy at trial entry (to ensure that there was no residual or
metachronous intraluminal disease) and were offered an end-of-trial colonoscopy at 5 years; in the two CT
arms, a colonoscopy to check for luminal recurrence was also undertaken at 2 years.
For those undergoing CEA testing follow-up, blood collection kits were sent directly to the patient, who
then attended their own general practice for phlebotomy. The blood was sent by post to the biochemistry
laboratory at John Radcliffe Hospital; the CEA testing analysis was carried out using a ADVIA Centaur
XP analyser (Siemens Healthcare Limited, Camberley, UK). If the blood CEA level was ≥ 7 µg/l above the
patient’s baseline level at trial entry, the test was repeated as soon as possible; if the second test was
also above this threshold, the general practitioner (GP) was asked to refer the patient urgently to the
local hospital.
Outcomes
The original protocol specified overall survival as the primary clinical outcome. However, by 2006 (after
3 years of recruitment) it was clear that we would fall far short of our original recruitment target. The Data
Monitoring and Ethics Committee (DMEC) also conducted an analysis of outcomes in the first 500 patients,
which showed that the recurrence and survival rates were substantially better than predicted from routine
data. They therefore advised the Health Technology Assessment (HTA) programme in 2007 that the trial
would have insufficient power to assess mortality within the projected time scale (i.e. when all participants
had completed the 5-year follow-up) and that the primary outcome should be changed to surgical
treatment of recurrence with curative intent.
Surgical treatment of recurrence with curative intent is, therefore, reported here as the primary clinical
outcome. Overall mortality is reported here as the main secondary clinical outcome. Other pre-specified
secondary clinical outcomes reported are deaths from colorectal cancer, time to detection of recurrence
and post-recurrence survival.
Data on treatment of recurrence and treatment intent were recorded on case report forms (CRFs) by local
National Cancer Research Network (NCRN) staff (who had access to the full clinical records).
Information on deaths was collected by flagging each participant at the Office for National Statistics (ONS)
central registry; cause of death was abstracted from death certificates.
Sample size
The trial originally set out to recruit 4800 participants in order to detect a 4% improvement in survival
from 49% to 53% in any of the more intensive follow-up arms (CEA testing, CT or CEA testing and CT),
compared with the minimum follow-up arm. In advising the change in main outcome from mortality to
recurrence treated surgically with curative intent, the DMEC estimated that to detect a 6% absolute
difference between minimum follow-up and any of the three other more intensive follow-up arms with
80% power (two-sided alpha 0.05) would require 205 patients in each of the four follow-up arms; 590
subjects allocated to each factorial group (CEA measurement and CT imaging) would provide 80% power
to detect a 3% absolute difference in the factorial comparison. We therefore planned to stop recruitment
when we reached a minimum of 1180 participants.
Randomisation and blinding
Patients were independently allocated at random in a 1 : 1 ratio to receive or not receive each of the
factorial interventions (CEA measurement and CT imaging) using the telephone randomisation service
METHODS
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provided by the Oxford Clinical Trials Unit. Research staff at the local centres telephoned the unit, giving
patient details and answering a checklist of questions to confirm eligibility. A computerised algorithm
was applied using the method of minimisation to balance the patient characteristics within each centre.
The balancing variables were adjuvant chemotherapy, gender and age group (three strata).
As this was a pragmatic open trial, it was not possible to conceal allocation arm either to the participants
or to the clinical team involved in patient management. However, the research staff who abstracted
the outcome data from the clinical notes were employed by the local NCRN teams, independent of
the investigators.
The initial protocol had specified that the primary analysis would be undertaken when all patients had
completed 5 years’ follow-up. As a result of the extended period of recruitment and the change in the
main outcome measure, the DMEC subsequently advised that an interim analysis should be undertaken
(and randomisation code broken) in September 2012, when all participants had completed a minimum of
3 years’ scheduled follow-up. This interim analysis programme was undertaken first using dummy variables
for the allocation arms and the code was not broken until the syntax was agreed. The analysis reported
here (based on outcome data collected up to November 2014) applies the same syntax as for the interim
analysis but necessarily was not blinded to allocation arm.
Statistical methods for clinical analyses
The primary analysis was undertaken using IBM Statistical Product and Service Solutions (SPSS) Statistics
version 20 (IBM Corporation, Armonk, NY, USA). When feasible, crude data are presented with statistical
comparison made between randomisation arms based on chi-squared tests for binary or categorical data,
the t-test or analysis of variance as appropriate for comparing group means and the Kruskal–Wallis test for
comparing medians. Time to recurrence was analysed by the Kaplan–Meier method, to take account of both
time-censoring and the difference in the number of recurrences detected in each arm. The plots of time to
recurrence are compared by the log-rank Mantel–Cox statistic. Adjusted odds ratios (ORs) for the main
outcome were calculated by binary logistic regression, entering all the baseline characteristics, reported in
Table 1, into the model. Cox HRs are also reported for comparison of overall mortality. As there was
significant interaction between the CEA testing and CT factorial groups (p = 0.013), the main comparison
made in presenting the results is between the three intensive arms and the minimum follow-up arm.
Protocol adherence and withdrawal
Adherence to protocol was ascertained through NHS hospital and laboratory records. A secondary per-protocol
analysis is reported that excludes the 308 patients who received any unscheduled investigation or had missed
more than one scheduled examination. Reasons for withdrawal were sought. All patients who withdrew
gave consent for continued follow-up through ONS mortality records. The analysis of other clinical outcomes
(including recurrence and recurrence treated surgically with curative intent) is censored on the date of
withdrawal.
Protocol amendments
The two significant amendments to the original 2003 protocol during the trial have been described above.
The initial protocol did not specify the single CT scan at 12–18 months in the minimum follow-up arm;
66 patients were randomised before this change took effect in May 2005. Surgical treatment with curative
intent rather than overall survival was specified as the main outcome in 2007, when it became clear that
we could not recruit the number of participants necessary to estimate an effect on overall survival with
adequate statistical power.
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Chapter 3 Results
Characteristics of participants
The allocation of the 1202 participants recruited between January 2003 and August 2009 to each
randomisation arm and subsequent drop-out is shown in the Consolidated Standards of Reporting Trials
(CONSORT) diagram (Figure 1). The characteristics of participants at trial entry are shown in Table 1. The
mean age of participants was 69 years, 61.2% were male, 29.1% had significant comorbidity, 40.5% had
received adjuvant chemotherapy and 11.6% had received pre-operative radiotherapy (for rectal cancer)
before randomisation. The randomisation method was successful in achieving a good balance between
randomisation arms and factorial comparison groups, with no statistically significant or important
difference in age, gender, ethnicity, tumour site and stage, adjuvant treatment or smoking habit.
Length and completeness of follow-up
The duration of scheduled follow-up to detect recurrence was 5 years and the median time elapsed since
trial entry during which we collected mortality data was 8.7 years at the data lock in the autumn of 2014.
As mortality data were collected through ONS flagging of death certificates, follow-up is complete except
for three participants who have emigrated from the UK. As the CONSORT diagram (see Figure 1) shows,
clinical follow-up continued until a trial end point (death, recurrence or end of scheduled follow-up),
except in the 145 patients who withdrew during the study. The main reasons for withdrawal were
deteriorating health (40.0%), dislike of the allocated mode of follow-up (41.4%) and moving away
(13.8%). Although Table 2 shows that there was no significant difference between arms in the number
of withdrawals, there were more withdrawals from dislike of the allocated mode of follow-up in the
minimum arm (27/301, 9.0%) than in the more intensive arms (32/901, 3.5%), and the median length
of follow-up was shorter.
Detection of recurrence
During the 5 years of scheduled follow-up, cancer recurrence was detected in 203 (16.9%) participants
(see Table 2). Two-thirds of recurrences (134, 66.0%) were detected by a scheduled follow-up
investigation: 87 (64.9%) by CT, 43 (32.1%) by CEA measurement and four at colonoscopy (either by
colonoscopy or other investigation initiated at the consultation) (2.98%). Fewer recurrences were detected
in the minimum arm than in the intensive follow-up arms (12.6% vs. 18.3%; p = 0.02).
The Kaplan–Meier plots in Figure 2 show the detection of recurrence over time. The difference between
the three more intensive arms and the minimum arm in detection of recurrence does not reach statistical
significance (log-rank p = 0.07), but the difference in detection of recurrence treatable with curative intent
is significant (log-rank p = 0.005), with none detected in the minimum follow-up arm after the end of
year 2.
Curative treatment and survival
The proportion of participants with recurrence surgically treated with curative intent was 6.3% (76/1202)
overall, with little difference according to Dukes’ stage (stage A, 5.1%; stage B, 7.4%; stage C, 5.6%;
p = 0.56). Table 3 shows that surgical treatment of recurrence with curative intent was two to three times
higher in each of the three more intensive follow-up arms (7.5% overall) than in the minimum follow-up
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arm (2.7%) (absolute difference 4.8%; p = 0.003). The adjusted OR was 2.5 for CEA measurement only
(p = 0.04) and 3.7 for CT only (0.002).
Both CT and CEA testing were significantly more effective than minimum follow-up in detecting recurrence
treatable with curative intent, but there was no evidence of any additive effect (the adjusted OR for the
combined CT + CEA testing arm was not significantly different from that for CT or CEA testing alone). More
recurrences were detected in the CT arm than in the CEA testing arm (9.4% vs 6.3%; p = 0.16). Although
the difference between CEA testing and CT was not statistically significant, the factorial comparison
showed a significant absolute benefit only for CT (absolute difference 3.7%; p = 0.01).
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FIGURE 2 Kaplan–Meier plots of time to diagnosis of (a) any recurrence and (b) any recurrence surgically treatable
with curative intent by follow-up group.
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The number of patients with recurrence detected during scheduled follow-up who were still alive at the
time of analysis was also higher in the intensive follow-up arms (4.8% vs. 2.3%; p = 0.07), as was the
median post-recurrence survival (27.3 vs. 14.6 months; p = 0.11), but neither difference is statistically
significant. Of the 76 patients treated surgically with curative intent, around half (40, 52.6%) were still
surviving at a median of 4 years and 4 months from time of surgery. Median survival after surgical
treatment of recurrence with curative intent was 52.3 months (compared with 14.2 months in those
treated without curative intent). The absolute difference in the proportion of patients surviving after
curative intent treatment in the intensive arms compared with the minimum arm was 2.2% (p = 0.29);
the absolute difference in the factorial comparison was 1.3% for both CEA testing and CT (p = 0.20).
There were no significant differences in the total number of deaths, or in the number of deaths attributed
to colorectal cancer (see Appendix 2), between the four randomisation arms or two factorial groups. The
Kaplan–Meier overall survival curve by randomisation arm (Figure 3) confirms that there was no significant
difference in survival over time between arms (log-rank p = 0.45). The Cox hazard ratio (HR) comparing the
minimum and intensive arms and adjusting for the characteristics in Table 1 showed a non-significant
advantage to minimum follow-up of 0.87 [95% confidence interval (CI) 0.67 to 1.15]. These CIs imply an
upper limit to the absolute mortality benefit from intensive follow-up of 3.8%; the lower limit means that
it is impossible to exclude the possibility of harm. However, the outcome of patients treated for recurrence
with curative intent is favourable.
Adherence to protocol
The extent of adherence to the follow-up protocol is shown in Table 4. Patient adherence to follow-up
was good. For imaging, 85% attended for every CT scan and only 3% missed more than one scheduled
CT. For CEA testing, 70% of patients attended for every scheduled blood test and only 9% missed more
than one test. Although clinician adherence appears less impressive (with 10.5% of participants receiving
unscheduled blood CEA level tests, 12.0% receiving unscheduled CT scans and 10.1% receiving unscheduled
colonoscopies without documented evidence that these investigations had been triggered by symptomatic
presentation), the protocol required investigation of any symptoms presenting between scheduled follow-up
tests. Substantially more unscheduled tests were carried out in patients not receiving regular CT scans, with
16.3% compared with 4.7% receiving one or more unscheduled CEA tests (p< 0.001), 18.6% compared
with 3.7% receiving one or more unscheduled CT scans (p < 0.001) and 16.0% compared with 4.3%
receiving one or more unscheduled colonoscopies (p < 0.001).
Per-protocol analysis
The results of a per-protocol analysis are shown in Table 5, excluding the 340 (28.3%) patients who
missed more than one scheduled investigation or received any unscheduled investigation. The results are
consistent with the intention-to-treat (ITT) analysis but effect estimates are higher: the rate of detection of
treatable recurrence in the more intensive arms compared with the minimum follow-up was 9.3% versus
2.1% (p = 0.001). As with the ITT analysis, Table 4 and Figure 3 show that there is no difference in overall
survival between arms (log-rank p = 0.36). The Cox HR comparing the minimum and intensive arms and
adjusting for the characteristics in Table 1 again showed no significant difference in survival (HR 0.97,
95% CI 0.72 to 1.32).
Summary of main findings
The proportion of participants with recurrence treated with curative intent was lower than predicted from
earlier trials (6.0% overall) but it was three times higher in the more intensive arms than in the minimum
follow-up arm. The proportion of recurrences treatable with curative intent was not related to stage at
DOI: 10.3310/hta21320 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 32
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mant et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
15
diagnosis of the primary cancer. Both CEA testing (with a single CT scan) and regular CT are effective
modes of follow-up, but conducting CEA testing and CT imaging in parallel provided no additional benefit.
There was no statistical difference in overall deaths or colorectal cancer deaths in the minimum compared
with the intensive follow-up arms after a median of 8.7 years of observation. If there is a survival benefit
from intensive follow-up in the first 10 years, it is very unlikely to exceed 4% in absolute terms and harm
cannot be excluded, although this seems unlikely as the survival rate of patients treated for recurrence
is high.
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FIGURE 3 Kaplan–Meier plots of overall survival of the cohort by follow-up group for (a) the intention-to-treat
population and (b) the per-protocol population.
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Chapter 4 Economic evaluation
Introduction
The FACS trial included a prospective economic analysis, which was designed to be integral to the trial,
collecting information on resource use, survival and HRQoL to investigate the cost-effectiveness of
each policy. This chapter reports an analysis of the FACS health economic data collected up to 5 years
post randomisation for each patient. The details of the study design and interventions have been reported
previously in this report.
Methods
Resource use
The planned economic evaluation was a cost–utility analysis conducted from the perspective of the UK
NHS. Given the trial’s modified primary end point, cost-effectiveness results were additionally expressed
using recurrence treated surgically with curative intent (henceforth referred to as treatable recurrence) as
the outcome measure.
The analyses used trial data collected for the duration of the 5-year clinical follow-up period; survival data
were also censored at 5 years for all patients. CEA testing was organised centrally by the research team
and the number of tests performed was calculated from laboratory test reports received. Numbers of CT
scans, colonoscopies, radiography and MRI scans performed were extracted from hospital records by NCRN
nurses in each centre and reported on CRFs. Information on confirmed recurrences and treatments
(curative or palliative surgery, radiotherapy and chemotherapy) was also obtained from hospital records.
Using questionnaires sent at 12, 24, 36, 48 and 60 months post randomisation, patients reported
health-care services that they had used over the previous 12 months, including visits to GPs, practice
nurses, stoma care nurses, hospital outpatient clinics and visits from district nurses. Patients also reported
if they had been admitted to hospital, how many times they had been admitted and their total number
of hospital inpatient nights.
Costs
Patient-level resource-use data were costed using national average unit costs (expressed in 2012–13 UK
pounds sterling) obtained from a variety of sources.42–44 The unit costs used are shown in Table 15,
Appendix 3. Full details of the costing methods used can also be found in Appendix 3, with abridged
information given below. As the time horizon for the analysis was 5 years, costs (and outcomes) were
discounted to present values at an annual rate of 3.5%.45
For each patient, and for each follow-up year, each CEA test, CT scan, colonoscopy, radiography and
MRI scan was costed by applying the appropriate unit cost. The associated visits to practice nurses and
hospital outpatient clinics for each of these screens/scans were costed by adding the relevant visit cost.
Additional practice nurse and outpatient clinic visits, together with visits to GPs and stoma nurses, and
home visits from district nurses, were also costed using the appropriate per-visit costs. When costing
inpatient hospital admissions for reasons other than surgery for recurrence, an average oncology bed-day
cost was used to multiply the number of hospital inpatient days reported.44
For each patient with recurrence who underwent surgery, the type of surgical procedure performed was
recorded and mapped to its corresponding Healthcare Resource Group (HRG) code(s). This code was then
located in the NHS Reference Cost database and a weighted average was taken of the cost (and length of
stay) across all specialties and subcategories within that code.44 When a patient’s recorded hospital stay
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exceeded the average length of stay for their particular procedure, additional days were costed using an
excess bed-day cost for an oncology ward.44
For radiotherapy and/or chemotherapy administered following recurrence, expert clinical opinion provided
information on standard regimens (drug doses, frequency and duration) for curative and palliative
management; these were then costed (see Table 15, Appendix 3) and assigned to patients accordingly.
Recurrence treated surgically with curative intent
Local NCRN staff extracted data on recurrences and treatment intent (curative vs. non-curative) from
hospital clinical records.
Survival
Each patient entered into the study was flagged with the ONS central registry; monitoring is ongoing,
but for this analysis it is censored at 5 years post randomisation. Cause of death was abstracted from
death certificates.
Health-related quality of life
At baseline and at 12, 24, 36, 48 and 60 months, patients completed the EQ-5D, three-level version
(EQ-5D-3L), a questionnaire assessing levels of generic HRQoL and containing questions on five domains:
mobility, self-care, usual activities, pain/discomfort and anxiety/depression.35 Responses to the EQ-5D-3L
were converted into a single HRQoL index score on a scale where 0 is representative of dead and 1 of full
health with an algorithm developed using data from a sample of the UK general population.46,47
Quality-adjusted life-years
For each patient in the study, quality-adjusted life-years (QALYs) were generated by adjusting observed
survival time in each year for the average level of EQ-5D HRQoL reported during the same year (e.g. 1 year
survived with an average level of HRQoL of 0.6 gives 0.6 QALYs). These calculations were repeated for
each of the 5 years, discounted and then summed to give the total number of QALYs experienced.
Statistical analysis
Data were missing on 11% of resource-use and EQ-5D data items at 5 years. Data were assumed to be
missing at random and multiple imputation (MI) using chained regression equations was used to impute
missing values (for additional details see Appendix 3). In line with recommendations, imputation was
performed separately for each trial arm and five values were predicted for each missing data point,
essentially creating five different data sets.48 Rubin’s rule, which acknowledges and accounts for variability
within as well as between imputed data sets, was used when summarising data across the five data sets.49,50
Continuous resource use data, costs and QALYs were summarised as means and standard errors (SEs), and
categorical data were summarised as numbers and percentages. The three imaging follow-up policies were
each compared with minimum follow-up and with each other using mean costs, cases of recurrence treated
surgically with curative intent and QALYs. Parametric 95% CIs were estimated around mean differences,
and incremental cost-effectiveness ratios (ICERs) were calculated.51 The ICER is estimated by dividing the
difference in cost by the difference in effect between policies and provides an estimate of the additional
cost of producing one additional unit of effect (here, an additional treatable recurrence or a QALY) when
moving from one policy to another. To interpret an ICER reporting the incremental cost of detecting an
additional treatable recurrence, knowledge is required about whether or not such an ‘intermediate’ end
point translates into actual patient benefit, such as improved life expectancy, quality of life, or both. ICERs
already encompassing ‘final’ end points such as the QALY are more readily interpretable and, with much
research already conducted to suggest that society’s maximum willingness to pay for a QALY in England
and Wales lies between £20,000 and £30,000, can be compared against this threshold.45 Policies with
ICERs below this threshold are generally considered cost-effective.
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Non-parametric bootstrapping was used to explore the uncertainty surrounding the QALY-based
cost-effectiveness results and to construct cost-effectiveness acceptability curves, which describe a range
of possible cost-effectiveness thresholds.52
The analyses were performed using Stata® version 12 (StataCorp, College Station, TX, USA).
Sensitivity analysis
To assess the influence of the MI procedure, an alternative complete-case analysis was performed.
Uncertainty around the mode of delivery and processing costs of the CEA test was also examined;
the baseline test cost of £7.50 was increased (decreased) to £10 (£5).
Results
Table 6 reports the demographic and clinical characteristics for patients in each arm of the trial; the groups
were well balanced.
TABLE 6 Baseline demographics, clinical characteristics and 5-year recurrence and survival by randomisation group
Characteristics
Minimum
follow-up
(N= 301)
CEA testing
follow-up
(N= 300)
CT follow-up
(N= 299)
CEA testing and CT
follow-up (N= 302)
Age (years), mean (SD) 69.3 (8.5) 68.8 (8.3) 69.0 (8.9) 69.5 (8.1)
Gender (male), n (%) 184 (61.1) 184 (61.3) 183 (61.2) 185 (61.3)
Treated comorbidity, n (%) 93 (30.9) 90 (30.0) 81 (27.1) 86 (28.5)
Pre-treated with chemotherapy, n (%) 123 (40.9) 121 (40.3) 118 (39.5) 125 (41.4)
Pre-treated with radiotherapy, n (%) 35 (11.7) 32 (10.7) 34 (11.4) 38 (12.6)
Site of cancer, n (%) (N = 295) (N= 293) (N= 290) (N = 292)
Right colon 103 (34.9) 93 (31.7) 96 (33.1) 90 (30.8)
Left colon 105 (35.6) 118 (40.3) 96 (33.1) 110 (37.7)
Rectum 87 (29.5) 82 (28.0) 98 (33.8) 92 (31.5)
Dukes’ stage, n (%) (N = 292) (N= 289) (N= 293) (N = 287)
A 69 (23.6) 54 (18.7) 71 (24.2) 60 (20.9)
B 131 (44.9) 144 (49.8) 132 (45.1) 146 (50.9)
C 92 (31.5) 91 (31.5) 90 (30.7) 81 (28.2)
Recurrence diagnosed at 5 years, n (%) 38 (12.6) 56 (18.7) 61 (20.8) 48 (15.9)
Treated surgically, n (%) 14 (36.8) 25 (44.6) 30 (49.2) 22 (45.8)
Surgery was with curative intent,
n (%)
8 (21.1) 19 (33.9) 28 (45.9) 21 (43.8)
Deaths at 5 years, n (%)a 48 (16.0) 53 (17.7) 57 (19.1) 46 (15.2)
Attributable to colorectal cancer,
n (%)a
28 (58.3) 35 (66.0) 36 (63.2) 28 (60.9)
SD, standard deviation.
a Numbers for these events vary from those presented in the FACS clinical paper as survival is censored at 5 years for
this analysis.
DOI: 10.3310/hta21320 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 32
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mant et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
21
Recurrence treated surgically with curative intent
Table 6 also shows the number of patients diagnosed with recurrence in each trial arm after 5 years of
clinical follow-up. This figure was 38 (12.6%) in the minimum follow-up arm, 56 (18.7%) in the CEA
testing arm, 61 (20.4%) in the CT arm and 48 (15.9%) in the CEA testing and CT arm. The numbers of
treatable recurrences were 8 (21.1%), 19 (33.9%), 28 (45.9%) and 21 (43.8%), respectively. When
averaged across all patients in each trial arm, the mean numbers of treatable recurrences per patient were
0.027, 0.063, 0.094 and 0.070, respectively.
Resource use and costs
Table 7 summarises the mean resource use by trial arm over the 5-year follow-up period and Table 8 reports
the corresponding mean total costs by trial arm. A more detailed version of these tables by year of follow-up
is shown in Table 16 in Appendix 3.
The mean total undiscounted 5-year cost per patient in the minimum follow-up arm was lower than in the
other three arms. Setting aside the costs of implementing the different intensive follow-up policies, Table 8
shows that much of this cost difference arose because fewer recurrences were diagnosed and treated with
minimum follow-up. The CT policy was on average £1516 (95% CI £292 to £2740; p = 0.02) per patient
more costly than the CEA testing policy, with much of this additional cost attributable to the CT scans
and associated hospital outpatient visits. The combined CEA testing and CT policy was the most costly
alternative, being on average £798 (95% CI –£674 to £2270; p = 0.29) per patient more costly than the CT
arm. Much of this difference arose because of higher costs of (non-surgery related) hospital readmissions.
TABLE 7 Mean (SE) resource use per patient by trial arm at 5 years
Description
Minimum
follow-up
(N= 301),
mean (SE)
CEA testing
follow-up
(N= 300),
mean (SE)
CT follow-up
(N= 299),
mean (SE)
CEA testing and CT
follow-up (N= 302),
mean (SE)
CEA tests at 5 years 0.70 (0.12) 11.55 (0.26) 0.12 (0.05) 11.03 (0.26)
CT scans at 5 years 1.09 (0.06) 1.01 (0.06) 5.44 (0.13) 5.47 (0.13)
Colonoscopies at 5 years 0.57 (0.04) 0.50 (0.04) 1.10 (0.04) 1.15 (0.05)
Radiography at 5 years 0.04 (0.01) 0.03 (0.01) 0.35 (0.08) 0.33 (0.07)
MRI scans at 5 years 0.01 (0.01) 0.01 (0.01) 0.03 (0.02) 0.01 (0.01)
≥ 1 surgeries for recurrence at 5 years, n (%) 14.00a (4.7) 25.00 (8.3) 30.00 (10.0) 22.00 (7.3)
Radiotherapy for recurrence at 5 years, n (%) 7.00 (2.3) 4.00 (1.3) 9.00 (3.0) 9.00 (3.0)
Chemotherapy for recurrence at
5 years, n (%)
14.00 (4.7) 32.00 (10.7) 32.00 (10.7) 32.00 (10.6)
GP visits at 5 years 2.95 (0.33) 3.15 (0.31) 3.39 (0.72) 3.74 (0.55)
Practice nurse visits at 5 years 2.19 (0.74) 13.48 (0.67) 1.95 (0.65) 12.01 (0.27)
District nurse visits at 5 years 0.75 (0.22) 3.89 (0.97) 1.86 (0.39) 2.71 (0.85)
Stoma nurse visits at 5 years 0.65 (0.15) 0.39 (0.10) 0.68 (0.11) 0.85 (0.21)
Outpatient clinic attendances at
5 years
6.49 (0.62) 6.17 (0.63) 11.65 (0.48) 12.07 (0.58)
Other inpatient bed-days at 5 years 1.98 (0.40) 2.68 (0.51) 2.14 (0.46) 4.52 (1.41)
a One patient known to have had two surgeries.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
The final row in Table 8 shows mean (SE) total discounted 5-year costs of £3138 (£334), £4613 (£438),
£6048 (£393) and £6796 (£618) for the minimum, CEA testing, CT and combined CEA testing and CT
follow-up arms, respectively.
Survival
At 5 years, 48 (16.0%) patients in the minimum follow-up arm had died, as had 53 (17.7%) in the CEA
testing arm, 57 (19.1%) in the CT arm and 46 (15.2%) in the CEA testing and CT arm. The mean (SE)
total number of discounted life-years in each of these arms at 5 years was 4.37 (0.05), 4.32 (0.05), 4.33
(0.05) and 4.37 (0.05), respectively.
TABLE 8 Mean (SE) costs (£) per patient by trial arm at 5 years (undiscounted and discounted)
Description
Minimum
follow-up
(N= 301),
mean (SE)
CEA testing
follow-up
(N= 300),
mean (SE)
CT follow-up
(N= 299),
mean (SE)
CEA testing and CT
follow-up (N= 302),
mean (SE)
CEA tests at 5 years 5.28 (0.88) 86.65 (1.94) 0.88 (0.35) 82.72 (1.95)
CT scans at 5 years 142.88 (8.06) 131.59 (7.20) 711.31 (17.06) 714.63 (17.31)
Colonoscopies at 5 years 295.42 (21.33) 258.71 (19.34) 567.29 (22.96) 590.59 (24.13)
Radiography at 5 years 1.46 (0.43) 1.07 (0.37) 13.91 (3.03) 13.25 (2.92)
MRI scans at 5 years 1.90 (1.10) 1.91 (1.10) 6.39 (4.60) 2.53 (1.26)
Subtotal: tests/scans 446.95 (25.48) 479.93 (23.13) 1299.78 (37.90) 1403.72 (40.24)
≥ 1 surgeries for recurrence at
5 years, n (%)
423.96 (114.07) 760.80 (152.64) 1042.49 (191.40) 613.61 (128.45)
Radiotherapy for recurrence at
5 years, n (%)
37.21 (18.39) 29.97 (18.00) 37.46 (18.52) 49.53 (22.10)
Chemotherapy for recurrence at
5 years, n (%)
492.27 (134.59) 1199.36 (203.61) 1224.99 (208.08) 1206.70 (205.39)
Subtotal: treatment for recurrence 953.44 (206.43) 1990.13 (296.99) 2304.93 (323.66) 1869.85 (291.44)
GP visits at 5 years 132.67 (14.84) 141.72 (14.11) 152.55 (32.54) 168.17 (24.97)
Practice nurse visits at 5 years 29.42 (9.89) 181.09 (8.98) 26.14 (8.71) 161.28 (3.66)
District nurse visits at 5 years 29.28 (8.41) 151.89 (37.91) 72.60 (15.33) 105.84 (33.15)
Stoma nurse visits at 5 years 27.91 (6.49) 16.86 (4.37) 29.25 (4.78) 36.74 (9.06)
Outpatient clinic attendances at
5 years
935.19 (88.75) 888.86 (91.26) 1677.34 (68.43) 1737.63 (83.33)
Other inpatient bed-days at 5 years 730.73 (148.76) 989.31 (190.43) 793.01 (170.91) 1670.18 (520.73)
Subtotal: health-care contacts 1885.21 (208.89) 2369.73 (259.95) 2750.88 (202.60) 3879.83 (576.04)
Mean total costs at 5 years 3285.60 (344.99) 4839.80 (458.05) 6355.60 (411.54) 7153.40 (652.70)
Of which: year 1 1062.80 (189.74) 1558.17 (227.07) 1925.07 (226.04) 2018.09 (252.35)
Year 2 1038.66 (183.29) 1363.56 (227.26) 2024.73 (207.47) 1876.54 (184.15)
Year 3 477.66 (81.83) 758.13 (159.95) 764.63 (149.44) 1672.28 (436.85)
Year 4 336.31 (43.47) 623.87 (144.29) 756.35 (156.58) 698.35 (130.26)
Year 5 370.16 (34.57) 536.06 (85.40) 884.82 (136.60) 888.14 (98.30)
Mean total 5-year discounted costs
at 5 years
3138.15 (333.72) 4613.19 (438.35) 6048.37 (393.22) 6796.10 (617.78)
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Health-related quality of life
Table 9 shows the mean (SE) self-reported HRQoL of survivors by arm and year of follow-up. HRQoL
appeared lower from year 2 onwards with both minimum and combined CEA testing and CT follow-up.
However, only in the year 5 EQ-5D scores was any significant difference observed (and then only between
minimum and CEA testing follow-up). Appendix 3, Table 17 shows additional EQ-5D-3L data by domain
and indicates that a slightly higher proportion of patients in the minimum follow-up and combined CEA
testing and CT arms reported problems with pain and discomfort.
Figure 4 shows the mean EQ-5D scores and 95% CIs across all study patients. The mean scores in all trial
arms declined over time as the number of deaths increased.
Quality-adjusted life-years
The mean (SE) estimated discounted QALYs for the minimum follow-up arm, the CEA testing arm, the CT
arm and the combined CEA and CT arm were 3.61 (0.07), 3.66 (0.06), 3.62 (0.07) and 3.59 (0.07),
respectively (see Table 9).
Cost-effectiveness
Table 10 shows the cost-effectiveness results based on a treatable recurrence end point. The ICERs are
shown in the final row of the table and reveal that the lowest cost of detecting an additional treatable
recurrence is achieved when moving from minimum follow-up to CEA testing-only follow-up (£40,131).
The cost of detecting an additional treatable recurrence with CT over minimum follow-up, however, was
only slightly higher, at £43,392. When compared with CT, follow-up with CEA testing and CT was, on
average, more costly but detected fewer treatable recurrences.
The first row of Table 11 shows the mean total cost and QALY differences and associated ICERs for each
of the imaging policies compared with minimum follow-up. A move from minimum follow-up to CT or to
combined CEA testing and CT follow-up was, on average, more costly and produced fewer QALYs than a
move from minimum follow-up to CEA testing follow-up. This is reflected in the ICERs, with the additional
cost per QALY gained by moving from minimum follow-up to CEA (£25,951), lower than the ICER for CT
(£246,107). When compared with minimum follow-up, combined CEA testing and CT was more costly and
generated fewer QALYs, resulting in a negative ICER (–£208,347) and a dominated policy.
TABLE 9 Mean (SE) reported EQ-5D-3L HRQoL of survivors by trial arm and year and mean (SE) QALYs for
whole cohort
Description
Minimum follow-up
(N= 301)
CEA testing follow-up
(N= 300)
CT follow-up
(N= 299)
CEA testing and CT
follow-up (N= 302)
n Mean SE n Mean SE n Mean SE n Mean SE
Year 1 294 0.84 0.01 296 0.86 0.01 295 0.85 0.01 296 0.85 0.01
Year 2 290 0.82 0.01 282 0.84 0.01 282 0.85 0.01 290 0.81 0.02
Year 3 276 0.82 0.02 274 0.84 0.01 270 0.84 0.01 279 0.81 0.02
Year 4 265 0.83 0.01 258 0.85 0.01 260 0.82 0.02 269 0.81 0.02
Year 5 253 0.81 0.02 247 0.87a 0.01 242 0.85 0.02 256 0.81 0.02
Mean total 5-year
QALYs, adjusted for
survival
3.85 0.07 3.91 0.07 3.86 0.07 3.83 0.08
Mean total 5-year
discounted QALYs,
adjusted for survival
3.61 0.07 3.66 0.06 3.62 0.07 3.59 0.07
a Difference compared to minimum follow-up = 0.068, p< 0.001.
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FIGURE 4 Mean (95% CI) EQ-5D-3L single-index scores for all patients in each trial arm at each year.
TABLE 10 Cost-effectiveness results based on recurrences treated surgically with curative intent as the
outcome measure
Description
Minimum
follow-up
(n= 301)
CEA testing
follow-up
(n= 300)
CT follow-up
(n= 299)
CEA testing and
CT follow-up
(n= 302)
Cost per patient, mean (SE) £3138.15
(£333.72)
£4613.19
(£438.35)
£6048.37
(£393.22)
£6796.10
(£617.78)
Number of recurrences
treated surgically with
curative intent, per patient,
mean (SE)
0.027 (0.009) 0.063 (0.014) 0.094 (0.017) 0.070 (0.015)
Incremental results
CEA testing vs.
minimum
CT vs.
minimum
CEA testing vs.
CT
CEA testing and
CT vs. minimum
CEA testing
and CT vs. CT
Difference in mean costs
(95% CI)
£1475 (£405 to
£2545)*
£2910 (£1894 to
£3926)**
£1435 (£265 to
£2605)***
£3658 (£2258 to
£5058)**
£748 (–£650 to
£2145)
Difference in mean number
of recurrences treated
surgically with curative
intent, per patient (95% CI)
0.037 (0.004 to
0.070)***
0.067 (0.029 to
0.105)*
0.030 (–0.013 to
0.073)
0.043 (0.009 to
0.077)***
–0.024 (–0.068
to 0.020)
Incremental cost per
recurrence treated surgically
with curative intent detected
£40,131 £43,392 £47,347 £85,151 –£31,014
(dominated)
*p < 0.01, **p< 0.001, ***p< 0.05.
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TABLE 11 Base-case and sensitivity analysis average and incremental results
Description
Minimum follow-up
(n= 301)
CEA testing-only
follow-up (n= 300)
CT-only follow-up
(n= 299)
CEA testing and
CT follow-up
(n= 302)
Base-case analysis
Mean total costs (£) 3138 (334) 4613 (438) 6048 (393) 6796 (618)
Mean total QALYs 3.61 (0.07) 3.66 (0.06) 3.62 (0.07) 3.59 (0.07)
CEA test cost £5
Mean total costs (£) 3136 (334) 4586 (439) 6048 (393) 6770 (618)
Mean total QALYs 3.61 (0.07) 3.66 (0.06) 3.62 (0.07) 3.59 (0.07)
CEA test cost £10
Mean total costs (£) 3140 (334) 4641 (438) 6049 (393) 6822 (618)
Mean total QALYs 3.61 (0.07) 3.66 (0.06) 3.62 (0.07) 3.59 (0.07)
Outliers removed arm 4
Mean total costs (£) 3138 (334) 4613 (438) 6048 (393) 6064 (391)
Mean total QALYs 3.61 (0.07) 3.66 (0.06) 3.62 (0.07) 3.59 (0.07)
Complete-case
analysis (n = 129) (n = 151) (n = 147) (n = 146)
Mean total costs (£) 2771 (434) 3354 (505) 5413 (489) 5463 (722)
Mean total QALYs 3.73 (0.10) 3.78 (0.09) 3.72 (0.10) 3.89 (0.09)
Incremental results
CEA testing vs.
minimum follow-up
CT vs.minimum
follow-up
CEA testing and CT
vs. minimum
follow-up
Base-case analysis
Mean cost difference
(95% CI)
£1475
(£405 to £2545)*
£2910
(£1894 to £3926)**
£3658
(£2258 to £5058)**
Mean QALY difference
(95% CI)
0.06 (–0.12 to 0.24) 0.01 (–0.17 to 0.19) –0.02 (–0.20 to 0.17)
ICER (probability
cost-effective at
£20,000 per QALY)
£25,951 (41.95%) £246,107 (3.70%) –£208,347
(dominated) (0.15%)
CEA test cost £5.00
Mean cost difference
(95% CI)
£1449
(£379 to £2520)*
£2912
(£1896 to £3928)**
£3633
(£2233 to £5034)**
Mean QALY difference
(95% CI)
0.06
(–0.12 to 0.24)
0.01 (–0.17 to 0.19) –0.02 (–0.20 to 0.17)
ICER (probability
cost-effective at
£20,000 per QALY)
£25,499 (42.45%) £246,225 (3.65%) –£206,952
(dominated) (0.15%)
CEA test cost £10.00
Mean cost difference
(95% CI)
£1501
(£431 to £2570)*
£2909
(£1893 to £3925)**
£3682
(£2283 to £5082)**
Mean QALY difference
(95% CI)
0.06 (–0.12 to 0.24) 0.01 (–0.17 to 0.19) –0.02 (–0.20 to 0.17)
ICER (probability
cost-effective at
£20,000 per QALY)
£26,404 (41.60%) £245,990 (3.75%) –£209,742
(dominated) (0.15%)
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Figure 5 plots 2000 bootstrapped estimates of the mean discounted 5-year cost and QALY differences
for each imaging policy versus minimum follow-up. Figure 6 plots the associated cost-effectiveness
acceptability curves. CEA testing appears to offer the greatest potential for being cost-effective when
compared with minimum follow-up; however, uncertainty surrounds these 5-year results. At a threshold of
£20,000 per QALY, the probability of CEA testing being cost-effective is 41.95%, increasing to 49.85% at
a threshold of £30,000 per QALY.
Sensitivity analyses
Table 11 also shows results for the sensitivity analyses. The findings were not sensitive to changes in the
cost of the CEA test. However, a complete-case analysis showed combined CEA testing and CT to be
more cost-effective than in the base-case analysis. In particular, the mean (SE) discounted 5-year QALYs
for combined CEA testing and CT at 3.89 (0.09) were higher than for the other three arms [mean 3.74
(0.06)]. This was because, for patients with complete data, 5-year mortality was lower in the combined
CEA testing and CT arm (7.5%) than in the other three arms (mean 16.4%).
Correspondingly, then, the larger reduction in QALYs seen in the combined CEA testing and CT arm
following imputation was attributable to higher levels of mortality in patients with incomplete data in that
arm (26% compared with just 17% with minimum follow-up, 18% with CT and 22% with CEA testing)
and also to lower levels of HRQoL (e.g. in year 2 mean EQ-5D scores for surviving patients with incomplete
data in the minimum, CEA testing and CT follow-up arms were 0.78, 083 and 0.83, respectively, but in
the combined CEA testing and CT arm the level was 0.76).
Finally, two patients receiving combined CEA testing and CT follow-up reported substantially higher
inpatient bed-days (120 days and 200 days) than other patients being admitted to hospital, and this
resulted in unexpectedly high inpatient costs. After removing both patients and re-estimating the results,
the cost in the combined CEA testing and CT arm fell from £6796 to £6064, but the mean QALYs were
also reduced by 0.0017 and the policy remained dominated, with a low probability of being cost-effective
(1.55%).
TABLE 11 Base-case and sensitivity analysis average and incremental results (continued )
Incremental results
CEA testing vs.
minimum follow-up
CT vs.minimum
follow-up
CEA testing and CT
vs. minimum
follow-up
Outliers removed arm 4
Mean cost difference
(95% CI)
£1475
(£405 to £2545)*
£2910
(£1894 to £3926)**
£2926
(£1913 to £3938)**
Mean QALY difference
(95% CI)
0.06 (–0.12 to 0.24) 0.01 (–0.17 to 0.19) –0.02 (–0.21 to 0.17)
ICER (probability
cost-effective at
£20,000 per QALY)
£25,591 (41.15%) £246,107 (3.15%) –£151,716
(dominated) (1.55%)
Complete-case analysis
Mean cost difference
(95% CI)
£583
(–£751 to £1918)
£2642
(£1339 to £3945)**
£2692
(£980 to £4404)*
Mean QALY difference
(95% CI)
0.05 (–0.21 to 0.32) –0.01 (–0.30 to 0.27) 0.16 (–0.10 to 0.42)
ICER (probability
cost-effective at
£20,000 per QALY)
£10,730 (35.15%) –£232,771
(Dominated) (3.05%)
£17,034 (34.60%)
*p < 0.01, **p< 0.001.
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Discussion
The follow-up tests assessed in this trial – CEA testing and CT imaging – have been identified in meta-analyses
as the most promising current methods of detecting curatively treatable metastatic recurrence in patients
with colorectal cancer.14,53 However, the economic evidence assembled to date is quite meagre. Secco et al.54
reported some costs for patients in a randomised trial of risk-adapted FACS, but the analysis was not
comprehensive in economic methods or costs included and related to only a subset of patients.
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The one detailed published cost-effectiveness analysis of intensive versus conventional follow-up after
curative resection for colorectal cancer derived its effectiveness estimates from a meta-analysis of five
randomised trials, and reported that the number of life-years gained through intensive surveillance over
standard care was between 0.73 and 0.82 per patient depending on the trials included, with a resulting
ICER of £3402 per life-year gained.55 However, there was considerable heterogeneity in the follow-up
regimens across the trials included, an absence of patient-level data on resource use and costs and no
HRQoL information. This study is therefore the first comprehensive analysis able to draw on patient-level
cost and HRQoL data and with a reasonable sample size and 5-year follow-up.
Although this study has clear advantages over previous evaluations, a number of issues make it difficult
to draw definitive conclusions on the cost-effectiveness of intensive follow-up. First, there were no clear
differences in HRQoL between the trial arms. This is of interest in itself, as it does not support the perception
that more intensive follow-up may be associated with increased anxiety and hence lower quality of life.
The results from this trial show no evidence that patients in the CEA testing, CT or combined arms were
more likely to report problems on the anxiety domain of the EQ-5D (see Table 17, Appendix 3), with some
suggestion that, despite the slightly higher number of detected recurrences in the CEA testing and CT arms,
quality of life was slightly, albeit non-significantly, higher in these arms than in the minimum follow-up arm
(see Table 9) at most follow-up points. However, the absence of significant differences in HRQoL also meant
that quality-adjusted survival was primarily influenced by the observed survival differences, which then directly
influenced the cost-effectiveness analysis. As detailed above, however, the trial was not powered for survival,
and a first analysis of the data when all patients had completed a minimum of 3 years’ scheduled follow-up
showed not only no significant differences in the number of deaths between the intensive follow-up arms
and the minimum follow-up arm [18.2% (164/901) vs. 15.9% (48/301), respectively; difference 2.3%,
95% CI –2.6% to 7.1%], but an unexpected 2% aggregate survival advantage with minimum follow-up.56
Although longer-term follow-up (median 8.7 years) has shown that survival in the minimum follow-up arm
has now fallen below that of the intensive follow-up arms (albeit not statistically so), the short-term survival
advantage associated with minimum follow-up has influenced the cost-effectiveness results presented in this
paper. The increase in recurrences treated with curative intent observed in the FACS trial would have been
expected to translate into a small survival advantage and, as shown above and in Table 11, the CIs around
total mortality and QALYs are still consistent with a survival advantage being possible with intensive follow-up.
In an attempt to provide a somewhat fairer representation of the cost-effectiveness of intensive follow-up,
results were also presented using the trial’s primary end point of treatable recurrences detected. When
compared with minimum follow-up, CEA testing detected additional treatable recurrences (mean 0.037
recurrences per patient) at the lowest additional cost (mean £1475 per patient), giving an ICER of
£40,131. Whether or not this represents good value for money, however, can really be determined only by
extrapolating the associated patient benefit. For example, if detection of a recurrence at a stage at which it
could be managed surgically with curative intent was known to afford a patient an additional 2.5 QALYs,
then the equivalent cost per QALY gained from moving from minimum follow-up to using CEA testing
would be around £15,950 [£1475/(0.037 × 2.5)]. Threshold analyses (not shown) suggest that a benefit of
at least an additional two discounted QALYs over the course of a patient’s lifetime would be needed for
an ICER < £20,000. As noted above, however, there are few data available on life-years gained through
early identification of recurrence.
A second difficulty encountered is that an assessment of cost-effectiveness at 5 years is almost certainly
premature. Data in Table 6 showed fewer recurrences with minimum follow-up and suggest that, in that
arm, there may be a number of undetected recurrences that are still to present. With no new curatively
treatable recurrences presenting in that arm beyond 2 years, the majority of these as yet undiagnosed
recurrences will probably be incurable.56 In the longer term, therefore, mortality might be expected to
increase in the minimum follow-up arm and a survival advantage from intensive follow-up could manifest
with no additional intensive surveillance costs. Although data from this study show that it is unlikely that
CT or combined CEA testing and CT will be cost-effective, it is still possible that follow-up with CEA
testing could be proven to be cost-effective in the longer term.
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This economic analysis has some limitations. For example, 11% of data were missing on resource use
and HRQoL. A complete-case analysis suggested combined CEA testing and CT to be substantially more
cost-effective than in the base-case analysis; however, patients with complete data in that arm were not
representative of all patients in the combined CEA testing and CT arm. By imputing what may be
considered a relatively small number of missing data, it was possible to include all patients in the analysis
and, thus, to generate more reliable estimates.
A further limitation is that, in the case of patients with recurrence, data were not collected on therapies
given beyond those used to treat the initial recurrence. This should be mitigated to some extent, however,
by the inclusion of costs for health-care contacts with hospitals (outpatient clinics and inpatient admissions).
Conclusion
This study has generated detailed data on the costs and HRQoL of patients undergoing minimum and
intensive follow-up regimes for the detection of recurrence following colorectal cancer. However, drawing
definitive conclusions on cost-effectiveness using the FACS trial is impossible because the FACS data lack
the necessary statistical power to determine whether or not the benefit in detecting treatable recurrence
translates into a survival benefit. Analyses using both treatable recurrences and QALYs as end points
suggest CEA testing to be the most promising of the intensive follow-up regimes, but, with the former
approach, the longer-term data required to extrapolate from treatable recurrence to a final end point
(life-years or QALYs) so as to facilitate an assessment of value for money are difficult to find, while the
latter approach is influenced by overall survival in the FACS trial, which the trial was not powered to
detect. The longer-term follow-up of patients and the monitoring of new recurrences and survival should
help to ascertain whether or not CEA testing represents an efficient use of scarce health-care resources.
Meanwhile, it is recommended that an economic evaluation of follow-up in colorectal cancer should follow
good practice guidelines in viewing data from the FACS trial as being complementary to and used
alongside information from all other relevant data sources.57
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Chapter 5 Observational analysis of participants
with recurrence in the Follow-up After Colorectal
Surgery study
Introduction
The FACS trial provides an opportunity to evaluate the characteristics of those who develop recurrence in a
population of well-staged prospectively followed-up patients treated for colorectal cancer. Knowledge
of those patients most likely to relapse is informative with respect to follow-up and planning adjuvant
treatment strategies. For example, rectal cancer has a well-established tendency to recur locally; however,
the combination of total mesorectal excision and optimal chemoradiotherapy has reduced rates to < 10%
in modern series.58–61 Existing evidence on the pattern of recurrence after curative resection of colorectal
cancer is limited to retrospective audits,62–64 and data from high-quality randomised controlled trials are
lacking. Trials of adjuvant therapies for colon and rectal cancer reveal certain information on patterns of
recurrence, but these are by definition limited to more advanced-stage cancers requiring such treatments.65
The present lack of evidence has resulted in conflicting guidance with respect to whether or not the same
surveillance strategy should be offered to patients irrespective of the site and stage of the primary tumour.
Some guidance suggests additional follow-up strategies for rectal cancer,66,67 whereas others recommend
much less intensive follow-up for rectal cancer than for colon cancer.68,69 Furthermore, much uncertainty
exists with respect to whether or not early-stage cancers should be followed up at all, owing to the low
likelihood of recurrence. Consequently, there is a need to advance understanding of the pattern of
recurrence and benefit of follow-up in the era of modern management of both primary colorectal cancer
and recurrence.
Methods
This retrospective cohort analysis aggregates data from all four trial arms and is restricted to 1132 patients
(94.2%) for whom complete detailed data are available on initial stage and site of recurrence. The cut-off
date used for this analysis is 31 August 2012, by which time all patients had reached a minimum of
3 years of follow-up, with a median follow-up of 4.4 years since randomisation.
Categorical variables are presented as frequencies (percentages) and the chi-squared test used for
comparisons. The Kaplan–Meier method was utilised for survival analyses and the log-rank test used to
compare survival between groups; p < 0.05 was considered significant. Tables were produced using SPSS
version 22 and survival analyses were carried out using the ‘survival’ package in R (The R Foundation for
Statistical Computing, Vienna, Austria).
Results
Incidence of recurrence
A total of 189 participants (17%) developed recurrence during the median follow-up period of 4.4 years
(interquartile range 3.1–5.0 years). The mean age of participants with recurrence was 67.8 years, and 63%
were male (Table 12). Predictably, recurrence was more frequent in those with a more advanced-stage
primary tumour [Dukes’ A primary, 10% (26/249); Dukes’ B, 15% (81/537); Dukes’ C, 24% (82/346);
p < 0.0001] (Table 13). The incidence of recurrence also varied according to the site of the original tumour
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TABLE 12 Characteristics of participants who went on to develop recurrence at trial entry by site of primary tumour
Characteristic All (N= 189)
Right colon
(N= 51)
Left colon
(N= 68) Rectum (N= 70)
Age (years), mean (SD) 67.8 (8.9) 69.3 (9) 65.8 (9.6) 68.6 (7.9)
Male, n (%) 119 (63) 29 (56.9) 41 (60.3) 49 (70)
Concurrent treatment for other illness, n (%) 47 (24.9) 12 (23.5) 16 (23.5) 19 (27.1)
Chemotherapy prior to trial entry, n (%) 93 (49.2) 25 (49) 32 (47.1) 36 (51.4)
Radiotherapy prior to trial entry, n (%) 27 (14.3) 0 3 (4.4) 24 (34.3)
Dukes’ stage, n (%)
A 26 (13.8) 3 (5.9) 9 (13.2) 14 (20)
B 81 (42.9) 24 (47.1) 29 (42.6) 28 (40)
C 82 (43.4) 24 (47.1) 30 (44.1) 28 (40)
Smoking status, n (%)
Never smoked 74 (41.8) 21 (45.7) 27 (41.5) 26 (39.4)
Ex-smoker 87 (49.2) 22 (47.8) 32 (49.2) 33 (50)
Current smoker 16 (9) 3 (6.5) 6 (9.2) 7 (10.6)
Unknown 12 (6.3) 5 (9.8) 3 (4.4) 4 (5.7)
SD, standard deviation.
TABLE 13 Site of recurrence by site and stage of original tumour
Description
Site of primary tumour
Total Right colon Left colon Rectum
All patients in the trial, n 1132 379 421 332
Recurrences, n (%) 189 51 68 70
Liver only 50 9 (18.0) 23 (46.0) 18 (36.0)
Lung only 33 3 (9.1) 8 (24.2) 22 (66.7)
Liver and lung only 11 3 (27.3) 6 (54.5) 2 (18.2)
Locoregional only 41 14 (34.1) 14 (34.1) 13 (31.7)
Multisite/other 54 22 (40.7) 17 (31.5) 15 (27.8)
Description
Stage of cancer (Dukes’)
Total A B C
All patients in the trial, n 1132 249 537 346
Recurrences, n (%) 189 26 81 82
Liver only 50 10 (20.0) 25 (50.0) 15 (30.0)
Lung only 33 8 (24.2) 14 (42.4) 11 (33.3)
Liver and lung only 11 1 (9.1) 4 (36.4) 6 (54.4)
Locoregional only 41 4 (9.8) 22 (53.7) 15 (36.6)
Multisite/other 54 3 (5.6) 16 (29.6) 35 (64.8)
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[right-colonic primary, 14% (51/379); left-colonic primary, 16% (68/421); rectal primary, 21% (70/332);
p = 0.023] (see Table 13).
Site of recurrence
Two-thirds of the recurrences detected (124/189) were at a single site (liver, 50; lung, 33; and locoregional, 41),
with the remainder having recurrence at other or multiple sites. Overall, the liver was the most frequent site
of recurrence, with 42% (79/189) of all recurrences involving the liver. Interestingly, the distribution of
recurrent disease varied according to the stage and location of the primary tumour. Both locoregional
recurrence and recurrence at multiple/other sites were most frequently associated with more advanced-stage
primary tumours (see Table 13). Recurrence involving just the lung was most frequently associated with
rectal primary tumours (right colon, 3/33, 9%; left colon, 8/33, 24%; rectum, 22/33, 67%; p < 0.0001).
In addition, recurrence at sites other than the lung, liver or locoregionally or at more than one of those sites
varied according to the site of primary tumour (right colon, 25/65, 38%; left colon, 23/65, 35%; rectum,
17/65, 26%; p = 0.018).
Incidence of recurrent disease treatable surgically with curative intent
The primary outcome of the FACS trial was treatment of recurrence surgically with curative intent.
When the analysis is restricted to the 189 participants with complete data on site and stage of the primary
cancer, a total of 65 (34%) are known to have undergone treatment with curative intent (Table 14). Those
participants with recurrence from a lower-stage primary tumour were more likely to be resectable
(Dukes’ A, 13/26, 50%; Dukes’ B, 32/81, 40%; Dukes’ C, 20/82, 24%; p = 0.08). Although there was no
significant difference in the likelihood of recurrent disease being amenable to curative resection according
to the site of original tumour, a trend was apparent (right colon, 12/51, 24%; left colon, 23/68, 34%;
rectum, 30/70, 43%; p = 0.086).
Benefit of follow-up
The proportion of participants with recurrence surgically treated with curative intent taken as a proportion
of the whole trial cohort was similar for each Dukes’ stage (A, 13/249, 5%; B, 32/537, 6%; C, 20/346, 6%;
p = 0.80). As such, a key finding of the FACS trial was that the benefit of follow-up is independent of stage;
that is, although recurrence is less frequent in those with Dukes’ A primary tumours, it is more likely to be
treatable.56 By contrast, the benefit of follow-up did vary according to the site of the primary tumour. Those
participants with a rectal primary tumour were more likely to have a treatable recurrence detected during
the follow-up period (right colon, 12/379, 3%; left colon, 23/421, 6%; rectum, 30/332, 9%; p = 0.003).
TABLE 14 Proportion of patients with recurrence treatable with curative intent according to stage and site of
primary tumour
Description
Site of primary tumour
Total Right colon Left colon Rectum p-valuea
Recurrences, n 189 51 68 70
Treatable with curative intent, n (%) 65 12 (23.5) 23 (33.8) 30 (42.9) 0.086
Description
Stage of cancer (Dukes’)
Total A B C p-valuea
Recurrences, n 189 26 81 82
Treatable with curative Intent, n (%) 65 13 (50) 32 (39.5) 20 (24.4) 0.03
a p-value based on chi-squared statistic.
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Survival post recurrence
Of the 189 diagnosed with recurrent disease, 113 (60%, 106 specifically from recurrence and seven from
other causes) died during the follow-up period. Survival post recurrence differed according to both the site
(log-rank p = 0.01) and stage (log-rank p = 0.005) of the primary tumour (Figure 7a and b).
Survival post recurrence also differed according to the site of recurrent disease. Those with multisite
recurrence or metastatic recurrence at other sites had an inferior survival to those with single-site recurrence
in the liver, lung or locoregionally (see Figure 7c; log-rank p < 0.0001), consistent with the high proportion
of patients with these single-site recurrences undergoing surgical treatment with curative intent (liver only,
30/50, 60%; lung only, 13/33, 40%; locoregionally only, 16/41, 40%; multisite/other recurrence, 6/65, 9%).
Of those amenable to treatment with curative intent, around three-quarters (44/65, 67.7%) were still alive
at the end of the follow-up period. Neither the site nor the stage of the primary tumour influenced the
survival of those with recurrent disease treated with curative intent, although there was a trend towards
worse survival in those with a higher-stage primary tumour (Figure 8).
Discussion
This observational analysis reports on patterns of recurrence and post-recurrence survival in the prospectively
followed-up large cohort of patients curatively treated for Dukes’ A to C colorectal cancer in the FACS trial.
The rigour of investigative procedures undertaken to ensure that patients were free of disease prior to
recruitment affords an accurately staged population in which to assess the true incidence of disease
recurrence.
The pattern of recurrence observed in the FACS cohort is similar to that reported by other studies, with the
liver being the most common site of disease recurrence. The results also demonstrate a preponderance of
isolated lung recurrence from rectal tumours, supporting the contention that haematogenous spread occurs
from the rectum to the lungs via the iliac veins. The relatively low incidence of locoregional recurrence from
rectal primary tumours is consistent with modern management combining total mesorectal excision with
selective use of chemoradiotherapy. Indeed, locoregional recurrence was no more frequent in rectal
tumours than in colonic tumours. This is at odds with certain guidance that recommends the use of regular
proctosigmoidoscopy in the follow-up of rectal cancer patients.67
This analysis demonstrates clear differences between right-colonic, left-colonic and rectal primary tumours.
Right-colonic tumours resulted in fewer isolated recurrences in the liver, in the lung or locally than
recurrences from left-colonic or rectal tumours. This is in agreement with data demonstrating more
peritoneal and distant lymph node metastases in BRAF mutated and microsatellite unstable tumours,71
two features most commonly associated with right-sided cancers. The less favourable pattern of relapse
from right-colonic tumours plausibly extends to an inferior survival post relapse for these patients in the
FACS cohort. Indeed, in a recent consensus subtyping of colorectal cancer, the group with the highest
proportion of right-colonic tumours had the worse survival after relapse, whereas those with the lowest
proportion had the most favourable survival.72
Recurrence was, predictably, more frequent in those who were followed up with a higher-stage primary
tumour. However, as already noted,56 the benefit of follow-up was independent of the stage of the
primary tumour. That is, although participants with a higher-stage primary tumour were more likely to
have a recurrence detected during the follow-up period, it was less likely to be treatable. Indeed, it may
be that a higher-stage tumour at original diagnosis reflects not simply a later stage in the developmental
pathway of colorectal cancer, but rather a more aggressive tumour type, the prognostic implications of
which remain if recurrence occurs. These results support the use of equivalent follow-up strategies in
patients with early-stage cancers, as they derive equal benefit. This is a key finding, given that some
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FIGURE 7 Kaplan–Meier curves for post-recurrence survival for all participants with disease recurrence. (a) Dukes’
stage; (b) site of primary cancer; and (c) site of recurrence. Reprinted with permission, copyright © 2015 Wolters
Kluwer Health. From Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D, Primrose JN. Site and stage of colorectal
cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the
FACS randomized controlled trial. Ann Surg 2016;263:1143–7.70
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guidance currently states that there is a lack of evidence for follow-up after resection of stage I/Dukes’ A
colorectal cancer.66
In contrast to the observation for Dukes’ stage, the benefit of follow-up was dependent on the site of
the primary tumour. Patients with rectal tumours were three times as likely as those with right-colonic
tumour to have a treatable recurrence detected during the follow-up period. This supports the practice of
undertaking intensive follow-up for patients with rectal tumours similar to that for those with colonic
tumours, which is contrary to certain guidance.68,69
In conclusion, the FACS cohort demonstrates that characteristics of the primary colorectal tumour,
specifically site and stage, influence not only the likelihood of recurrence, but the distribution of recurrent
disease and post-recurrence survival. The influence of stage on outcome, even post recurrence, suggests
that the stages of primary colorectal cancer represent different disease biology rather than simply points on
the timeline of disease progression.
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The post-recurrence survival of participants with recurrence is shown according to stage of primary tumour
(see Figure 7a), site of primary tumour (see Figure 7b) and site of recurrent disease (see Figure 7c). All
include the number of patients at risk and p-value calculated using the log-rank method.
The post-recurrence survival of participants with recurrence treated surgically with curative intent is shown
according to stage of primary tumour (see Figure 8a) and site of primary tumour (see Figure 8b). All include
the number of patients at risk and the p-value calculated using the log-rank method.
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Chapter 6 Discussions and conclusions
Principal findings
This trial investigated two different strategies in the follow-up of patients having treatment for primary
colorectal cancer with curative intent: hospital-based imaging and CEA measurement in primary care in a
2 × 2 trial design. The two follow-up strategies were chosen because meta-analyses suggest that CEA
testing and CT imaging are the only practical and available modalities with significant potential to detect
curatively treatable recurrence. Endoscopy is well established in follow-up and its use is evidence based73
in the detection of metachronous polyps and rarely luminal recurrence. However, it is commonly only
performed 5 years after the initial resection, assuming that the colon is free of polyps at the time of
treatment of primary disease. The hospital-based imaging arms therefore had an additional 2-year
endoscopic examination scheduled in order to determine whether or not any additional recurrence may
be detected.
Other follow-up modalities were considered and rejected. Liver ultrasound lacks sensitivity and specificity,
as does clinical examination, and although MRI imaging is very sensitive in the detection of liver
metastases, it has limited utility elsewhere.14,53 CT–positron emission tomography (PET) was not widely
available when this trial was designed, is complex and expensive, and would be used only if it were shown
to be superior to the results obtained from modern CT scanners. No such evidence exists even from the
perspective of 2016 and, thus, the modalities chosen in the FACS trial remain the only practical and
useful tests.
Our results show that the proportion of patients treated with curative intent was around 6%, with little
difference according to stage. Intensive follow-up by either scheduled CEA testing, imaging or both
increased the likelihood of detecting such recurrences by around two to three times. The absolute
difference in the proportion of participants treated with curative intent was 3.6–6.7% in the ITT analysis
and 6.4–8.6% in the per-protocol analysis, indicating that between 12 and 20 patients need to be
followed up to identify one potentially curable recurrence. Over 50% of the patients treated surgically with
curative intent were still alive at a median of 8.7 years from trial entry and 4.4 years post recurrence,
somewhat higher than would be expected from prior reports.2,3
Although the proportion of recurrences treated with curative intent (and the success of such treatment) is
high compared with earlier reports, the absolute number of treatable recurrences detected is lower.14 This is
not explicable by differences in stage-specific case mix (detection of recurrences treatable with curative
intent was similar irrespective of stage) and neither is there any evidence that FACS trial participants were at
low risk of recurrence within stage (84.5% of stage C participants had received adjuvant chemotherapy).
Stage-specific overall survival of FACS trial participants is comparable with that reported in trials of adjuvant
chemotherapy such as MOSAIC.74
The probable explanation for the lower detection of treatable recurrence is the rigour of the investigative
procedures undertaken to ensure that no residual cancer was present at trial entry. It suggests that the
high rate of early recurrence reported from routine cancer statistics in England and Scandinavia75 reflects
residual disease that would have been detected with fastidious imaging. Before entry to the trial, all
patients had to have a CT scan of the chest, abdomen and pelvis and also a CEA test that was within
normal limits. Although this would now be the standard of care for most patients with colorectal cancer,
it certainly was not at the time that the trial was set up. It is, therefore, inevitable that many patients who
were classed by superficial staging as having Dukes’ stage A to C colorectal cancer would actually have
been in stage D and that these ‘occult’ metastases declared themselves relatively early after the patients
were managed for the primary cancer. Fastidious staging to detect metastatic disease will inevitably reduce
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the number of patients with recurrent disease detected by follow-up, hence reducing its cost-effectiveness.
It is one of the most important findings of the study that full staging of patients with primary colorectal
cancer is essential if they are to be managed optimally.
The comparison between intervention arms suggests that monitoring with CEA testing combined with
a single CT scan at 12–18 months is equally as effective as undertaking regular CT scanning. As CEA
testing can be done in primary care, it is likely to be more cost-effective than regular CT imaging, and this
is confirmed by the health economic analysis discussed in summary below. However, imaging is still
necessary to confirm recurrence, and, in the combined CEA testing and CT arm, two-thirds of recurrences
were first detected by CT. Indeed, in the factorial analysis, CT significantly outperformed CEA testing in
the detection of recurrence. The diagnostic performance of CEA as a monitoring test depends on the
frequency of testing and the algorithm used to interpret the result. The algorithm applied in the FACS trial
(refer for imaging if blood CEA level is ≥ 7 µg/l above baseline) achieves good specificity, but at the cost of
modest sensitivity.76 We are currently now investigating whether or not a higher sensitivity can be achieved
at an acceptable level of specificity by applying a diagnostic algorithm that takes account of change over
time and that has been applied successfully in interpreting CA125 levels when screening for ovarian cancer.77
The decision on whether or not the absolute benefit of follow-up is sufficient to justify its opportunity cost
will differ between health economies. The benefits of follow-up appear to be independent of diagnostic
stage because although there are fewer recurrences with earlier-stage tumours, they are more likely to be
curable, and so it makes no sense to apply stage-specific follow-up strategies.66 Because of the meticulous
investigation carried out before trial entry to exclude residual disease, our results also provide useful new
data on the timing of recurrence, which can strengthen the evidence base for choosing the optimal
frequency of testing. Duplication of monitoring tests does not appear to add value; the participants in our
CEA testing arm had a single CT scan at 12–18 months, when three recurrences were detected, but
otherwise there was no suggestion of benefit from monitoring with both CEA testing and CT.
Despite the size of the trial, it provides very limited precision in estimating survival. The observed 2–3%
apparent survival advantage in the minimum and maximal (CT plus CEA testing) follow-up arm is certainly
correct and it is based on ONS data. However, our sample size means that the survival estimates for each
arm are also imprecise. Even if 50% of the additional treatable recurrences detected in the more intensive
intervention arms were cured, the overall survival advantage would be very small (and the 95% CIs would
include the results we have actually observed). Even the possibility of harm cannot be excluded, although,
bearing in mind the excellent survival in the patients treated for single-site metastatic disease, this seems
unlikely. Furthermore, owing to the efficacy of modern treatments for advanced colorectal cancer,
differences in overall survival at 5 years may not be evident in any case.
Health economic and quality-of-life analysis
The analysis was principally based on the trial end point, which is surgical treatment of recurrent disease
with curative intent. The incremental cost per patient, compared with the minimum arm, ranged from
£40,131 with CEA testing through £43,392 with hospital-based imaging to £85,151 with CEA testing and
CT combined. As expected, CEA testing (combined with a single CT scan) is the most economical option,
and imaging costs more per patient by around 50%. The cost of the most intensive schedule, however, is
around four times that of CEA testing and, as there is no current clear advantage to using both modalities,
it is obvious that, in economic terms, CEA testing or imaging appears preferable. The trial was not
powered to detect a difference in overall survival. No difference was observed and by inference it could
not be more than 3%. Mean quality of life was also found to differ little between the arms of the study,
but, as expected, it did deteriorate over 5 years. Mean reported quality of life appeared to be significantly
better in the CEA testing arm only in year 5. The consequence of these results was that there was
little difference between arms in quality-adjusted survival. Combining cost and QALY differences, the
incremental cost per QALY gained for CEA testing compared with minimum follow-up was £25,951,
DISCUSSIONS AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
for CT compared with minimum follow-up was £246,107, and for the combined CEA testing and CT arm
was more expensive and less effective, resulting in a negative cost per QALY gained of –£208,347. A high
degree of uncertainty accompanied these results, with our analysis indicating a 42% probability that the
cost per QALY gained for CEA testing versus minimum follow-up was below a £20,000 threshold.
Observational analysis
The analysis of just those patients with recurrence at a median follow-up of 4.4 years demonstrates that
the characteristics of the primary tumour influence not only the likelihood of recurrence but also the
distribution of recurrent disease and survival post recurrence. These data suggest that disease biology
present at the time of diagnosis of primary disease remains relevant even after the diagnosis of recurrence.
Interestingly, whereas a key finding of the FACS trial is that all stages of primary tumour benefit equally
from follow-up, this was not the case for site of primary tumour. Patients with rectal cancers were
approximately three times as likely to have a treatable recurrence identified during follow-up as those with
right-colonic tumours. This directly supports undertaking equivalent follow-up in these patients, contrary to
certain guidance.68 Overall, this analysis demonstrates favourable outcomes for patients treated surgically
with curative intent for recurrence, supporting the use of this as a surrogate end point for the trial.
Strengths and weaknesses of the trial
The FACS trial is the largest follow-up trial in colorectal cancer that has been performed to date that
utilises modern diagnostic facilities and applies modern surgical and other management to those with
detected recurrence. Importantly, the trial was undertaken in a large number of hospital settings in
England, including small district general hospitals as well as large teaching centres. This aspect has ensured
that the results are generalisable throughout the NHS. Although many of the centres involved in the study
did not locally undertake surgery for recurrent disease, such as liver resection, it was mandated that all of
the patients managed in the trial had access through the multidisciplinary teams to surgical services that
would include liver and lung resection as well specialist surgery to deal with local recurrence when this was
not available locally. This type of service is now routine in the UK, although when the study began it was
not universal.
As well as examining the treatment modalities involved in follow-up, this trial contained economic and
quality-of-life evaluations in order to be able to determine the cost-effectiveness of follow-up. The trial
also enabled us to obtain tissue from the resected primary tumours that allow biomarker studies to be
undertaken. The combination of the clinical trial data with the availability of tissue for biomarkers is a
major advantage and one that will allow further research. In half of the study cohort (those in whom CEA
measurement was performed), serum was retained. This allows for the investigation of additional markers
without the need to repeat the study.
The major weakness in the study is that, although it is the largest well-designed follow-up study performed to
date, it is underpowered to look for differences in mortality between the treatment arms. The original study
design did envisage an overall survival end point. This, however, was based on the relapse rates available at
the time and commonly reported within colorectal cancer patients in the UK. This, for instance, envisaged a
relapse rate of approximately 70% at 5 years for patients in Dukes’ stage C and approximately 50% relapse
overall.78 However, it was clear from the run-in phase of the study that the relapse rate was not nearly as
high as had been predicted from national data. Indeed, the overall survival in the study was approximately
80% at 5 years and approximately 70% at 10 years (although the numbers reaching 10 years are very small).
As detailed above, these data are entirely compatible with studies on the adjuvant treatment of resected
colorectal cancer74 and almost certainly result from the fastidious pre-trial entry staging.
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Owing to the much lower recurrence rate observed during the run-in phase of the study, the primary end
point was changed to the treatment of recurrence surgically with curative intent. This was felt to be a
clinically meaningful end point that would still allow the benefit of follow-up to be assessed. It is accepted
that this end point is subject to ascertainment bias in so much as the outcome is not independent of
the method of follow-up. It is, however, generally acknowledged that the majority of recurrences will
present within 5 years79–81 and, therefore, by completion of 5 years of follow-up this should not be a
major issue.
The study also suffers from a relatively high level of withdrawals and protocol deviations. With respect to
withdrawals, this is perhaps to be expected in a study that lasts for many years in patients with cancer.
It is noteworthy that there were more withdrawals from some arms than from others. The highest number
of withdrawals was from the minimum follow-up arm, and in some cases this may represent a level of
concern over the lack of continuing follow-up. The most intensive of the arms also suffered from more
withdrawals, and in some cases this was documented to be because of the relatively onerous nature of the
follow-up schedule, requiring both regular blood tests and CT imaging. Reassuringly, however, there
is little difference in the outcome measures in the patients who were managed and analysed by the ITT
method as opposed to the per-protocol analysis. All of the patients in the study were flagged with the
ONS, and hence the death data, which include all patients in the study whether or not they withdrew,
are known to be accurate.
The study had a pragmatic design, so most aspects of patient management, including the pathological
examination of the primary tumour and the subsequent radiology, were done by local protocol. This has
the advantage of ensuring that the results from the trial are applicable across the NHS, with the obvious
unknown variations in practice. However, in respect of the pathology it may cause understaging (e.g.
whether a patient is in Dukes’ stage A or C depends on a fastidious examination for lymph nodes in the
mesentery of the resected specimen). If this is not undertaken diligently, a patient who is diagnosed as
being in Dukes’ stage A may actually be at stage C; however, as we have demonstrated that benefit of
follow-up is independent of disease stage, this appears to have made little difference to the results. There
was also no central review of CT scans or, indeed, any set protocol at all for conducting the examination of
these. It is commonly observed that different protocols and different scanners will have different sensitivity
for picking up metastatic disease. Again, this is likely to introduce a degree of variability into the results.
In addition, the multidisciplinary team process that patients go through once recurrent disease has been
detected varies considerably.82
Findings in context
Although other studies have been performed assessing the utility of follow-up in this setting,7–10,14,53,54,83,84
they are generally of historic significance only and, therefore, meta-analysis with the FACS trial is
inappropriate. The authors of these studies did not have available modern imaging techniques and, in
addition, procedures such as resection of colorectal liver metastases were usually not available. We know
from this present study that examinations that bring to light recurrent or metachronous luminal cancer
(five patients in total) can make only a very small contribution to the long-term outcome.
The Schoemaker study10 compared clinical follow-up with clinical follow-up plus CT and colonoscopy.
The conclusion was that, although liver metastasis was detected at an earlier stage in the intensive arm,
this did not change greatly the number of liver metastases resections performed. However, as the study
consisted of only 325 patients, it was underpowered to detect any difference between the two arms.
The MRC-funded UK CEA trial12 recruited a large number of patients (n = 1447). It was conducted
between 1982 and 1993, when patients with recurrent cancer were not managed as they are now
(i.e. with detailed imaging to determine the site of recurrence and subsequent appropriate management).
In the trial, patients who developed a CEA rise were randomised to either aggressive treatment that
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included a second-look laparotomy or a conservative approach. It was presumed that the second-look
surgery would be able to treat some patients with local recurrence, but, with hindsight, this was a flawed
strategy. It would not now be accepted that second-look surgery, on the basis of a rise in CEA level, is an
appropriate or adequate treatment.
Three other studies that commenced at or around the time of the FACS trial have, so far, not reported in
full. The Italian GILDA study85 examined the addition of ultrasound to CEA-based follow-up of colorectal
cancer patients, although, confusingly, rectal cancer patients were also permitted a CT scan. As ultrasound
is an insensitive method of examining for recurrence, and as all patients had regular CEA measurement,
it is unsurprising that the experimental arm in this study did not demonstrate benefit.85 A French study
registered on ClinicalTrials.gov (NCT00199654) examines the use of PET compared with conventional
imaging and CEA testing. The end point is time to diagnosis of recurrence, and the study authors planned
to recruit 376 patients. However, this study started in 2005 and has yet to report. The technology of
PET has changed radically since 2005 (now only CT–PET is performed); it is expensive, and with the end
point chosen the investigators will be unable to determine the effectiveness or cost-effectiveness of the
intervention in improving the outcome of patients with relapsed colorectal cancer. The mainly Scandinavian
COLOFOL study initiated in 2005 (NCT00225641) examines the use of CT/MRI and CEA testing either
twice (12 and 36 months) or more frequently (6-monthly for 2 years and then at 36 months).86 This is a
potentially large trial, with a recruitment target of 2500, so the results may be relevant to NHS practice
and some meta-analysis with the FACS trial may be possible.
Since 2005, significant changes in the way in which advanced colorectal cancer is managed have increased the
importance of detecting early metastatic disease. Chemotherapy, often with the addition of biological agents,
has increased the survival of patients with advanced colorectal cancer up to a median of 24 months without
surgical treatment.87 Perhaps a bigger advantage of chemotherapy is that it is possible to bring patients who
are found to have inoperable colorectal liver metastasis to operability; this is known to be associated with
long-term survival in many cases.88 Other treatments, including radioembolisation, are now available to treat
colorectal liver metastasis that were not available when this study began.89 Last, it has been shown that a
combination of liver resection and ablation of unresectable disease, using radiofrequency or other techniques,
can result in increased survival as demonstrated in a randomised trial.90 However, all of these later treatments,
which increase the length of survival even in the absence of cure, do make it more difficult to use the overall
survival end point in follow-up studies. Indeed, although this study originally set out to examine outcomes at
5 years, it is clear that any survival analysis will have to be extended to 10 years or possibly beyond.
Implications for health care
This study has significant implications for the way in which patients with primary colorectal cancer are
managed. It is evident that fully staging patients with primary colorectal cancer is paramount. In the case
of patients presenting with synchronous metastatic disease, the management plans are likely to be radically
different and may, for instance, include neoadjuvant chemotherapy prior to any surgical intervention. In
relation to the methods used in this trial, pre-operative CT imaging and post-operative CEA measurement
may seem to be appropriate in routine practice. Although detecting metastatic disease at presentation using
CT imaging before trial entry was the most common reason for exclusion from recruitment, it was also
noted that some patients were discovered not to have had full imaging of the colon prior to their colorectal
resection. Endoscopic imaging mandated by trial entry picked up a number of previously unknown second
primary tumours that required further surgery.
UK guidance on follow-up has suggested that patients should have at least one CT scan at 12–18 months
as a matter of routine, and this was adopted in the minimum arm of the FACS trial.41 It is the case,
however, that many centres perform more CT scans than the minimum recommended in the guidelines.
In this trial, we have been able to show that, with the end point of surgical treatment of recurrence with
curative intent, CEA testing in combination with a single scan at 18 months performs equally well in this
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respect. We have also been able to show that doubling up (i.e. conducting regular CT scans as well as
CEA blood tests) does not detect significantly more treatable recurrences.
National Institute for Health and Care Excellence guidance91 currently suggests that two CT scans should
be performed in appropriate patients in the first 3 years in addition to regular CEA measurement. These
guidelines were produced prior to the first publication from this trial. We are currently conducting a
secondary analysis of the diagnostic performance of CEA testing in the trial, which will help to inform
future guidance on the optimal testing interval, the threshold for initiating further investigation and the
need for adjuvant CT scans.
These results should impact on how patients in the UK are managed; they also have implications overseas.
We have been able to provide compelling evidence about which modalities are best at detecting treatable
recurrence, thereby allowing health-care professionals to make evidence-based judgements on what is best
in their particular setting. Our health economic modelling suggests that a single CT scan combined with
regular CEA measurement is the most cost-effective approach.
Recommendations for research
In terms of the future, we are now in the era of genomics and biomarkers. A great deal of work has been
carried out on the whole-genome sequencing of colorectal cancer, and different subtypes have been
identified that have a different prognosis both in the short term and when the cancer recurs.72 This study
suffers somewhat from the context of the clinical trials from which the material for analysis was derived,
and further useful insights may come from the UK GEL 100K initiative (www.genomicsengland.co.uk) and
other sequencing programmes. In addition, the immune response to colorectal cancer has emerged as a key
prognostic indicator. Specifically, the infiltration of T cells within the primary tumour strongly correlates with
outcome. Thus, patients with tumours demonstrating a high T-cell infiltrate have a far better prognosis than
those with very little, and certain data suggest that this is superior to traditional Dukes’ or TNM staging.92,93
It seems likely in the future that follow-up of patients with colorectal cancer will be based on a
combination of genetic analysis, biomarkers and traditional follow-up methodologies, as demonstrated by
the FACS trial. It may be that it will be possible to identify a group of patients in whom the risk of relapse
is so low that follow-up is not required. By contrast, it is also likely that patients will be identified who have
a very high chance of relapse, and in whom a targeted trial of follow-up might be undertaken.
One of the major advantages of the FACS trial is the translational studies that it will permit. The trial
provides a large cohort of well-staged patients with almost complete follow-up data and complete
mortality data. Tissue from the primary resection has been collected, and we will go on to acquire tissue
from the resection of metastases. The first translational study, funded by the HTA programme, will
determine whether or not the immune infiltrate of the primary tumours can identify a cohort of patients
who do not benefit from follow-up. This is of practical importance, as the techniques required to assess
the immune infiltrate of tumours can be carried out in any routine histopathological laboratory in the NHS.
Conclusion
Among patients who had undergone curative surgery for primary colorectal cancer, follow-up with intensive
imaging or CEA screening both provided an improved rate of recurrence treated with curative intent
compared with minimal follow-up. The trial is underpowered to determine the effect of follow-up on either
cancer-specific or overall survival, and no trend in favour of any strategy is evident from the perspective of
5 years of follow-up. It may be that a trend will be detected when follow-up for mortality is continued to
10 years, as we propose to do. Any survival advantage is, however, likely to be small, taking into account
the whole cohort, the large majority of whom did not relapse.
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Appendix 1 Pre-trial modelling
Introduction
A pre-trial economic model was devised to assess the probable costs, effects and cost-effectiveness of each
of the trial options and to identify areas in which it was likely to be particularly important to collect
information during the trial.
Methods
The model took recurrence rates over the 5 years from the primary episode, stage-specific survival and
initial stage distribution rates from the Wessex Colorectal Cancer Audit (based on 4466 audited cases).
As the trial protocol proposed to recruit patients in Dukes’ stages A to C only, patients whose initial
tumour was classified as stage D were excluded from the calculations. The overall survival rate of patients
with initial colorectal cancer in Dukes’ stages A to C in the Wessex data was around 50%. The cumulative
recurrence rate at 5 years was around 28%. The model assumed that, in routine care, 6% of patients with
recurrences would be successfully treated and survive for 5 years.
The model included initial estimates of the frequency and cost of investigative procedures (CEA tests,
ultrasound and CT scans, GP consultations) in normal care and by following the proposed trial protocol.
Unit costs were taken from national sources. To calculate investigative costs, the predicted number of CEA
tests, GP consultations, ultrasound and CT scans according to the protocol were adjusted by expected
survival, taking into account cancer- and non-cancer-related deaths. To estimate treatment costs, the
model assumed that all patients who were successfully treated and approximately 5% of patients who
were not successfully treated would undergo resection. It was also assumed that all patients with a
recurrence who were not successfully treated would have a period of palliative care.
The model estimated the effect of improving the colorectal cancer death rate and thus increasing the
proportion of patients surviving recurrence by means of each of the three active intervention groups of
the proposed study: CEA testing in primary care, hospital-based follow-up and combined follow-up. In the
combined follow-up group, the improvement was set to give a survival gain of 8% over no follow-up, in
line with the trial hypothesis. CEA testing in primary care was set to give a survival gain of approximately
4%, as was hospital-based follow-up. To obtain a 4% gain in overall survival, it was necessary for the
CEA testing or hospital-based follow-up interventions to increase the proportion of patients surviving
recurrence from 6% to 20%. To obtain an 8% gain in overall survival, it was necessary for the combined
interventions to increase the proportion of patients surviving recurrence from 6% to 39%.
Cost-effectiveness was calculated as the incremental cost per life-year gained of each option compared with
normal practice. Different discount rates were examined for costs and effects, ranging from 6% to 1.5%.
The following table gives all main model parameter values and results. Figure 9 shows how the cost per
life-year gained changes in each arm as the percentage improvement in colorectal cancer death rate alters.
Figure 10 shows the model’s baseline estimate of cost-effectiveness of the three colorectal cancer follow-up
strategies relative to no follow-up.
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Model parameter values and results
Parameter values
Protocol
Survival
adjusted
Year 1 Year 2 Year 3 Year 4 Year 5 5 years
Number of CEA tests
Group 1 (normal care) 0.00 0.00 0.00 0.00 0.00 0.00
Group 2 (CEA testing in
primary care)
4.00 4.00 2.00 2.00 2.00 10.40
Group 3 (hospital
follow-up)
0.00 0.00 0.00 0.00 0.00 0.00
Group 4 (CEA testing
and hospital care)
4.00 4.00 2.00 2.00 2.00 10.83
Number of GP consultations related to recurrence
Group 1 (normal care)
(assumed to be four
times the recurrence
rate)
0.33 0.33 0.33 0.07 0.07 0.81
Group 2 (CEA testing in
primary care)
4.00 4.00 2.00 2.00 2.00 10.40
Group 3 (hospital
follow-up)
0.33 0.33 0.33 0.07 0.07 0.85
Group 4 (CEA testing
and hospital care)
4.33 4.33 2.33 2.07 2.07 11.71
Number of ultrasound and radiography scans
Group 1 (normal care;
assumed that referrals
get CT)
0.00 0.00 0.00 0.00 0.00 0.00
Group 2 (CEA testing in
primary care)
0.08 0.08 0.08 0.02 0.02 0.21
Group 3 (hospital
follow-up)
2.00 2.00 1.00 1.00 1.00 5.20
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FIGURE 10 Cost-effectiveness of three colorectal cancer follow-up strategies relative to no follow-up.
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Parameter values
Protocol
Survival
adjusted
Year 1 Year 2 Year 3 Year 4 Year 5 5 years
Group 4 (CEA
testingand hospital
care)
2.08 2.08 1.08 1.02 1.02 5.64
Number of CT scans
Group 1 (normal care;
assumed that 50% of
consultations are
referred)
0.00 0.00 0.00 0.20 0.20 0.23
Group 2 (CEA testing in
primary care; assumed
to be twice the actual
recurrence rate)
0.16 0.16 0.16 0.03 0.03 0.42
Group 3 (hospital
follow-up)
2.00 2.00 1.00 1.00 1.00 5.20
Group 4 (CEA testing
and hospital care)
2.16 2.16 1.16 1.03 1.03 5.86
Number of colonoscopies
Group 1 1.00 0.00 0.00 0.00 1.00 1.393
Group 2 1.00 0.00 0.00 0.00 1.00 1.452
Group 3 1.00 0.00 0.00 0.00 1.00 1.452
Group 4 1.00 0.00 0.00 0.00 1.00 1.511
Recurrence rate from Dukes’ stage A, B and C tumours (Wessex registry)
All 0.10 0.19 0.25 0.26 0.28
Successful treatment rates
Assumed
Improvement in
colorectal cancer
death rate
Proportion of
recurrences
surviving
Proportion of
recurrences
not surviving
Proportion of
recurrences
operated on
Group 1 (normal care;
data from Wessex
Colorectal Cancer
Audit)
0 0.06 0.94 0.11
Group 2 (CEA testing in
primary care)
0.20 0.26 0.74 0.30
Group 3 (hospital
follow-up)
0.20 0.26 0.74 0.30
Group 4 (CEA testing
and hospital care)
0.39 0.45 0.55 0.48
Survival probability
based on above Year 1 Year 2 Year 3 Year 4 Year 5 (Gain)
Group 1 (normal care;
Wessex registry)
0.856 0.744 0.657 0.585 0.54
Group 2 (CEA testing in
primary care)
0.876 0.775 0.695 0.625 0.58 3.96%
Group 3 (hospital
follow-up)
0.876 0.775 0.695 0.625 0.58 3.96%
Group 4 (CEA testing
and hospital care)
0.895 0.806 0.732 0.666 0.62 7.92%
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Parameter values
Protocol
Survival
adjusted
Year 1 Year 2 Year 3 Year 4 Year 5 5 years
Unit costs (£)
Cost of radiography 71
Cost of ultrasound scan 35
Cost of CT scan 185
Cost of colonoscopy 175
Cost of outpatient
appointment
63
Cost of resection 6000
Cost of CEA testing
(£6.50 + £1.50
postage/packing)
8
Cost of palliative care 10,000
Cost of GP consultation 14
Five-year results: cost (£) per life-year gained compared with normal practice
Group 2 (CEA testing in
primary care)
209
Group 3 (hospital
follow-up)
9911
Group 4 (CEA testing in
primary care and
hospital care)
5647
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Appendix 2 Colorectal cancer-specific survival
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FIGURE 11 Cumulative survival by intervention arm: colorectal cancer deaths only.
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Appendix 3 Follow-up After Colorectal Surgery
health economics
Costing methods
The unit cost for each CEA test recorded included consumables and laboratory processing costs. CEA tests
were generally conducted by practice nurses but, because patients reported visits to health-care professionals
separately, a practice nurse visit was not included as part of the CEA test unit cost to avoid double-counting.
Cross-checks of the annual numbers of CEA tests and patient-reported practice nurse visits were performed,
and when the number of practice nurse visits reported was lower than the number of CEA tests an upwards
adjustment to the number of practice nurse visits was made so that that numbers for both variables were
equivalent.
Computerised tomography scans, colonoscopies, radiography and MRI scans were costed using the sources
listed in Table 15; these investigations were conducted at hospital outpatient clinics, but as with CEA tests,
the associated clinic visit was counted separately and not included as part of these investigations. Again,
cross-checks were performed and when the number of outpatient clinic visits reported was lower than the
sum of the number of CT scans, colonoscopies, radiography and MRI scans, an upwards adjustment to the
number of visits was made so that numbers for both variables were equivalent.
TABLE 15 Unit costs (£) used in the analysis and sources of information (2012/13)
Resource-use item Unit cost (£) Source
Tests/investigations
CEA test 7.50 £6.00 for laboratory analysis plus £1.50 for postage and packing –
trial-participating hospital
CT scan 130.72 NHS reference costs 2012/1344 – average of codes RA08A, RA09A,
RA10Z–RA14Z, RA50Z. Diagnostic imaging outpatients, medical oncology
Chest radiography 40 Finance department, trial participating hospital
MRI 191.05 NHS reference costs 2012/1344 – average of codes RA01A, RA02A,
RA03Z–RA07Z. Diagnostic imaging outpatients, medical oncology
Colonoscopy 514.00 NHS reference costs 2012/1344 – code FZ51Z – diagnostic colonoscopy,
aged ≥ 19 years, colorectal surgery day case
Treatment for recurrence
Surgery Individual procedures were mapped to one or more HRG codes and the
weighted average of 2012/13 NHS reference costs44 for each mapped
HRG code (elective inpatients) was calculated
6980.80 Code AA12 – intermediate intracranial procedures except trauma with
brain tumours or cerebral cysts
8945.16 Code AA06 – major intracranial procedures except trauma with brain
tumours or cerebral cysts
7361.79 Code DZ02 – complex thoracic procedures
3719.05 Code DZ53 – major or intermediate thoracic procedures
5158.88 Code FZ66/FZ67 – very major/major small intestine procedures, aged
≥ 19 years
6936.06 Code FZ66 – very major small intestine procedures, aged ≥ 19 years
continued
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TABLE 15 Unit costs (£) used in the analysis and sources of information (2012/13) (continued )
Resource-use item Unit cost (£) Source
7471.52 Code FZ73/FZ74/FZ75 – very complex/complex large intestine
procedures/proximal colon procedures
8155.33 Code FZ73/FZ74 – very complex/complex large intestine procedures
10,500.74 Code GA03 – very complex open hepatobiliary or pancreatic
procedures
9450.05 GA03/GA04 – very complex/complex open hepatobiliary or pancreatic
procedures
8517.09 Code GA03/GA04/GA05 – very complex/complex/very major open
hepatobiliary or pancreatic procedures
4242.29 Code GA06/GA07/GA13 – major/intermediate open hepatobiliary or
pancreatic procedures/laparoscopic hepatobiliary or pancreatic
procedures
2741.87 Code GA07/GA10 – intermediate open hepatobiliary or pancreatic
procedures/laparoscopic/open cholecystectomy
4068.17 Code GB01/GB08 – very major/complex endoscopic or percutaneous,
hepatobiliary or pancreatic procedures
795.11 Code GB04 – minor endoscopic or percutaneous, hepatobiliary or
pancreatic procedures, aged ≥ 19 years
1098.63 Code GB07 – minor diagnostic endoscopic retrograde
cholangiopancreatography
3865 Code HC04 – extradural spine intermediate
5476.86 Code LB60/LB61/LB62 – complex/major open or percutaneous, kidney
or ureter procedures, aged ≥ 19 years/major laparoscopic kidney or
ureter procedures, aged ≥ 19 years
16,358.63 Code LB71 – total pelvic exenteration
4289.45 Code – MA06/MA26 complex/major open or laparoscopic, upper or
lower genital tract procedures for malignancy
Chemotherapy
First-line therapy drugs per 21-day cycle
Oxaliplatin 130 mg/m2,
once
18.25 100mg/20ml (£6.32) and 50mg/10 ml (£5.61) from NHS eMIT.94 Body
surface area of 1.79 m2 assumed
Capecitabine 1000mg/m2,
twice daily, days 1–14
41.16 500-mg tablets, 120 per pack (£47.84) and 150mg tablets, 60 per
pack (£8.34) from NHS eMIT.94 Body surface area of 1.79 m2 assumed
Bevacizumab (Avastin,
Roche) 7.5 mg/kg, once
1409.72 100mg/4 ml (£242.66) and 400mg/16ml (£924.40) from the BNF
2015.42 Average weight is assumed to be 76.5 kg
Second-line therapy drugs per 21-day cycle
Irinotecan 180mg/m2, once
per cycle
31.20 300mg/15ml (£25.58) and 40mg/2 ml (£5.62) from NHS eMIT.94 Body
surface area of 1.79 m2 assumed
Fluoroacil 2400 mg/m2
infusion, once
3.47 5 g/100ml (£3.47) from NHS eMIT.94 Body surface area of 1.79 m2
assumed
Fluoroacil 400 mg/m2
bolus, once
4.46 500mg/10ml (£0.96) and 250mg/10 ml (£3.50) from NHS eMIT.94
Body surface area of 1.79 m2 assumed
Folinic acid 300 mg, once 89.95 300mg/30ml (£89.95) from the BNF 201542
Aflibercept (Zaltrap,
Sanofi-Aventis) 4 mg/kg,
once
1182.60 200mg vial (£591.30) and 100mg vial (£295.65) from the BNF 2015.42
Average weight is assumed to be 76.5 kg
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For patients with recurrence who underwent one or more surgeries, the type of surgical procedure
performed was recorded along with hospital admission and discharge dates. Using the HRG4 + 2012/13
Reference Costs Grouping programme from the National Casemix Office, the Office of Population,
Censuses and Surveys Classification of Surgical Operations and Procedures code for each type of surgery
was identified and mapped to a corresponding HRG code(s).95 HRG codes were then located in the NHS
Reference Cost database, a weighted average was taken of the cost (and length of stay) across all
specialties (excluding paediatrics) and subcategories within that code, and then the resulting costs were
applied to the appropriate patients.44 When a patient’s hospital stay was known to exceed the average
length of stay for their particular procedure, additional days were costed using an excess bed-day cost for
an oncology ward.44
Detailed information was not collected on types of radiotherapy and/or chemotherapy received by patients
with recurrence; instead, expert clinical opinion provided information on standard regimens, doses, frequency
and duration of treatments, and Table 15 shows the resulting estimated radiotherapy and chemotherapy
unit costs. Radiotherapy treatment schedules varied depending upon whether a recurrence was treated with
curative intent or palliatively. Radical radiotherapy was assumed to involve a complex planning session and
25 sessions of treatment. Palliative radiotherapy was assumed to consist of a simple planning session followed
by five sessions of treatment. For patients recorded as having received radiotherapy, treatment was assumed to
have been radical if the patient also underwent surgery with curative intent following recurrence. Radiotherapy
was assumed to have been palliative if the patient underwent surgery without curative intent or if the patient
TABLE 15 Unit costs (£) used in the analysis and sources of information (2012/13) (continued )
Resource-use item Unit cost (£) Source
Radiotherapy
With curative intent
Radical radiotherapy
planning session
733.92 NHS reference costs 2012/1344 – average of codes SC40Z, SC41Z,
SC51Z, SC52Z – preparation for conformal/IM radiation therapy (RAD
worksheet)
Radical radiotherapy
fraction cost
121 NHS reference costs 2012/1344 – code SC23Z – deliver a fraction of
complex radiotherapy (RAD worksheet)
With palliative intent
Palliative radiotherapy
planning session
281.53 NHS reference costs 2012/1344 – average of codes SC45Z–SC50Z –
preparation for simple/superficial radiotherapy (RAD worksheet)
Palliative radiotherapy
fraction cost
91.00 NHS reference costs 2012/1344 – code SC22Z, deliver a fraction of
radiotherapy (RAD worksheet)
Longer-term follow-up
GP clinic attendance 45 PSSRU 201343 (assuming attendance duration of 11.7 minutes),
section 10.8b GP unit costs
Visits to practice nurse 13.43 PSSRU 201343 (assuming attendance duration of 15.5 minutes),
section 10.6
District nurse at home 39.00 PSSRU 2013,43 section 10.1 community nurse
Stoma care nurse 43.00 NHS reference costs 2012/1344 – code N24AF – specialist nursing –
stoma care services, adult, face to face
Oncology outpatient clinic
attendance
144 NHS reference costs 2012/1344 – code 370 – consultant-led medical
oncology clinic attendance
Excess inpatient bed-day
on oncology ward
369.79 NHS reference costs 2012/1344 – weighted average of elective inpatient
excess bed-day costs for medical oncology
BNF, British National Formulary; eMIT, electronic Market Information Tool; IM, intensity modulated; PSSRU, Personal Social
Services Research Unit; RAD, radiotherapy.
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was not treated surgically for their recurrence. Patients receiving chemotherapy for recurrence and who
survived at least 1 year from recurrence were assumed to have completed eight cycles of the first-line regimen
shown in Table 15. Patients who died within 1 year of recurrence were assumed to have progressed mid-way
through their remaining survival time and to have spent half of the time receiving the first-line chemotherapy
regimen and half receiving the second-line regimen.
Additional practice nurse and outpatient clinic visits, together with visits to GPs and stoma nurses and home
visits from district nurses, were also costed for each patient using appropriate unit costs from a variety of
sources including Personal Social Services Research Unit and NHS Reference Costs (see Table 15).43,44 When
costing inpatient hospital admissions reported by patients, and to avoid double-counting for those patients
who had undergone surgery for recurrence, one hospital admission and the appropriate number of
surgery-related inpatient hospital days recorded by staff were subtracted from patients’ annual self-reported
data. The remaining hospital inpatient days were costed using an average oncology bed-day cost taken
from the NHS Reference Costs.44
Multiple imputation
The MI approach uses predictions from regression models specified for each individual variable with
missing data to fill in the missing data points. The form of each regression equation is dependent upon the
type of data to be imputed, for example when imputing whether or not radiotherapy was given post
recurrence (yes/no), a logistic regression was specified. When imputing the EQ-5D single-index score, a
linear regression with prediction mean matching was used to ensure values were not predicted outside the
permissible range (–0.594 to 1). Variables with complete data were used as predictors in each regression
model (e.g. age and gender) along with all other variables to be imputed.
Table 16 gives a detailed breakdown, by each resource use category, of mean resource use and
undiscounted costs per patient by trial arm and year of follow-up. Table 17 shows the proportion of
surviving patients reporting some or severe problems on each domain of the EQ-5D, by year and arm.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
TA
B
LE
16
M
ea
n
re
so
u
rc
e
u
se
an
d
u
n
d
is
co
u
n
te
d
co
st
s
p
er
p
at
ie
n
t
b
y
tr
ia
l
ar
m
an
d
ye
ar
o
f
fo
llo
w
-u
p
R
es
o
u
rc
e
it
em
M
ea
n
(S
E)
re
so
u
rc
e
u
se
o
r
n
(%
)
re
ce
iv
in
g
re
so
u
rc
e
M
ea
n
co
st
[S
E
(£
)]
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
Y
ea
r
1
C
EA
te
st
s
0.
20
(0
.0
4)
3.
22
(0
.0
5)
0.
04
(0
.0
2)
3.
10
(0
.0
6)
1.
50
(0
.2
8)
24
.1
8
(0
.4
1)
0.
28
(0
.1
2)
23
.2
2
(0
.4
1)
C
T
te
st
s
0.
30
(0
.0
3)
0.
28
(0
.0
3)
1.
37
(0
.0
3)
1.
40
(0
.0
3)
38
.6
5
(3
.6
1)
37
.0
4
(3
.7
8)
17
9.
25
(4
.3
3)
18
3.
09
(4
.5
6)
C
ol
on
os
co
py
0.
08
(0
.0
2)
0.
06
(0
.0
1)
0.
12
(0
.0
2)
0.
14
(0
.0
2)
42
.6
9
(8
.5
4)
30
.8
4
(7
.4
6)
63
.6
1
(1
0.
10
)
73
.1
9
(1
0.
35
)
Ra
di
og
ra
ph
y
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
09
(0
.0
2)
0.
10
(0
.0
2)
0.
13
(0
.1
3)
0.
13
(0
.1
3)
3.
61
(0
.7
6)
3.
84
(0
.8
4)
M
RI
sc
an
s
0.
01
(0
.0
0)
0.
00
(0
.0
0)
0.
01
(0
.0
1)
0.
01
(0
.0
0)
1.
27
(0
.9
0)
0.
00
(0
.0
0)
2.
56
(1
.2
7)
1.
27
(0
.8
9)
Su
rg
er
y
6
(1
.9
9%
)
5
(1
.6
7%
)
7
(2
.3
4%
)
7
(2
.3
2%
)
17
7.
09
(7
3.
93
)
14
2.
52
(6
3.
65
)
25
0.
79
(9
9.
68
)
18
4.
28
(7
1.
08
)
C
he
m
ot
he
ra
py
4
(1
.3
3%
)
12
(4
.0
0%
)
15
(5
.0
2%
)
15
(4
.9
7%
)
16
0.
01
(7
9.
67
)
47
0.
12
(1
33
.1
9)
55
5.
22
(1
43
.8
5)
54
9.
71
(1
42
.4
6)
Ra
di
ot
he
ra
py
3
(1
.0
0%
)
0
(0
.0
0%
)
4
(1
.3
4%
)
4
(1
.3
2%
)
17
.3
8
(1
2.
94
)
0.
00
(0
.0
0)
17
.5
0
(1
3.
03
)
17
.3
2
(1
2.
90
)
G
P
vi
si
ts
0.
97
(0
.1
2)
1.
06
(0
.1
2)
0.
95
(0
.1
3)
1.
08
(0
.1
4)
43
.4
2
(5
.4
2)
47
.5
2
(5
.4
3)
42
.7
7
(5
.9
2)
48
.7
3
(6
.5
1)
PN
vi
si
ts
1.
38
(0
.7
6)
4.
27
(0
.6
3)
0.
59
(0
.1
9)
3.
26
(0
.0
6)
18
.4
8
(9
.5
4)
57
.4
1
(8
.4
4)
7.
91
(2
.5
4)
43
.8
1
(0
.8
0)
D
N
vi
si
ts
0.
55
(0
.1
7)
1.
62
(0
.7
0)
1.
30
(0
.3
6)
0.
85
(0
.6
0)
21
.4
0
(6
.5
3)
63
.3
6
(2
7.
17
)
50
.6
3
(1
4.
15
)
33
.2
4
(2
3.
44
)
SN
vi
si
ts
0.
34
(0
.1
1)
0.
23
(0
.0
7)
0.
36
(0
.0
8)
0.
40
(0
.1
0)
14
.4
9
(4
.7
9)
9.
83
(3
.0
1)
15
.4
2
(3
.3
3)
17
.3
4
(4
.4
3)
O
ut
pa
tie
nt
vi
si
ts
1.
42
(0
.1
1)
1.
44
(0
.1
7)
3.
17
(0
.3
1)
3.
24
(0
.2
7)
20
4.
66
(1
6.
52
)
20
7.
07
(2
4.
05
)
45
6.
75
(4
4.
48
)
46
6.
81
(3
9.
10
)
In
pa
tie
nt
st
ay
s
0.
13
(0
.0
3)
0.
15
(0
.0
3)
0.
19
(0
.0
4)
0.
14
(0
.0
3)
32
1.
63
(1
04
.5
2)
46
8.
15
(1
17
.2
8)
27
8.
76
(5
6.
95
)
37
2.
24
(1
63
.0
0)
Y
ea
r
2
C
EA
te
st
s
0.
16
(0
.0
3)
3.
44
(0
.0
9)
0.
02
(0
.0
1)
3.
29
(0
.0
9)
1.
17
(0
.2
2)
25
.8
0
(0
.6
5)
0.
18
(0
.1
0)
24
.6
9
(0
.6
5)
C
T
te
st
s
0.
49
(0
.0
3)
0.
48
(0
.0
3)
1.
62
(0
.0
5)
1.
50
(0
.0
5)
64
.2
7
(4
.2
5)
62
.3
1
(4
.3
0)
21
2.
04
(6
.6
7)
19
5.
65
(6
.6
8)
C
ol
on
os
co
py
0.
07
(0
.0
2)
0.
08
(0
.0
2)
0.
54
(0
.0
3)
0.
51
(0
.0
3)
37
.5
7
(8
.0
9)
39
.4
1
(8
.2
7)
27
5.
05
(1
4.
85
)
26
3.
81
(1
4.
81
)
Ra
di
og
ra
ph
y
0.
03
(0
.0
1)
0.
02
(0
.0
1)
0.
13
(0
.0
3)
0.
10
(0
.0
2)
1.
20
(0
.3
9)
0.
93
(0
.3
5)
5.
08
(1
.1
7)
4.
11
(0
.9
2)
co
nt
in
ue
d
DOI: 10.3310/hta21320 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 32
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mant et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
69
TA
B
LE
16
M
ea
n
re
so
u
rc
e
u
se
an
d
u
n
d
is
co
u
n
te
d
co
st
s
p
er
p
at
ie
n
t
b
y
tr
ia
l
ar
m
an
d
ye
ar
o
f
fo
llo
w
-u
p
(c
o
n
ti
n
u
ed
)
R
es
o
u
rc
e
it
em
M
ea
n
(S
E)
re
so
u
rc
e
u
se
o
r
n
(%
)
re
ce
iv
in
g
re
so
u
rc
e
M
ea
n
co
st
[S
E
(£
)]
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
M
RI
sc
an
s
0.
00
(0
.0
0)
0.
01
(0
.0
1)
0.
01
(0
.0
1)
0.
00
(0
.0
0)
0.
63
(0
.6
3)
1.
91
(1
.1
0)
1.
92
(1
.9
2)
0.
63
(0
.6
3)
Su
rg
er
y
7
(2
.3
3%
)
10
(3
.3
3%
)
14
(4
.6
8%
)
5
(1
.6
6%
)
19
2.
91
(8
0.
35
)
29
3.
49
(9
1.
96
)
45
7.
69
(1
26
.6
8)
14
9.
77
(6
7.
02
)
C
he
m
ot
he
ra
py
8
(2
.6
6%
)
9
(3
.0
0%
)
7
(2
.3
4%
)
9
(2
.9
8%
)
31
2.
37
(1
09
.1
4)
32
6.
32
(1
10
.1
4)
28
3.
92
(1
06
.5
4)
34
5.
66
(1
14
.7
7)
Ra
di
ot
he
ra
py
3
(1
.0
0%
)
1
(0
.3
3%
)
0
(0
.0
0%
)
2
(0
.6
6%
)
17
.3
8
(1
2.
94
)
12
.5
3
(–
)
0.
00
(0
.0
0)
14
.8
9
(1
2.
68
)
G
P
vi
si
ts
0.
70
(0
.1
0)
0.
94
(0
.1
8)
0.
50
(0
.1
0)
0.
89
(0
.2
1)
31
.3
7
(4
.6
1)
42
.2
4
(8
.1
2)
22
.6
7
(4
.6
5)
40
.0
2
(9
.5
2)
PN
vi
si
ts
0.
26
(0
.0
4)
3.
64
(0
.0
9)
0.
14
(0
.0
5)
3.
48
(0
.0
9)
3.
44
(0
.5
7)
48
.8
6
(1
.2
6)
1.
94
(0
.7
0)
46
.7
4
(1
.2
5)
D
N
vi
si
ts
0.
13
(0
.0
6)
1.
98
(0
.6
9)
0.
32
(0
.1
4)
0.
87
(0
.3
6)
5.
23
(2
.2
6)
77
.4
0
(2
6.
86
)
12
.4
4
(5
.4
2)
33
.8
9
(1
3.
86
)
SN
vi
si
ts
0.
08
(0
.0
4)
0.
08
(0
.0
4)
0.
11
(0
.0
4)
0.
07
(0
.0
2)
3.
23
(1
.8
7)
3.
24
(1
.6
8)
4.
80
(1
.5
4)
2.
93
(0
.9
7)
O
ut
pa
tie
nt
vi
si
ts
1.
64
(0
.1
8)
1.
54
(0
.1
4)
3.
41
(0
.1
6)
3.
68
(0
.3
7)
23
6.
43
(2
6.
25
)
22
2.
53
(2
0.
47
)
49
1.
24
(2
3.
41
)
52
9.
94
(5
3.
94
)
In
pa
tie
nt
st
ay
s
0.
09
(0
.0
3)
0.
07
(0
.0
2)
0.
23
(0
.0
8)
0.
11
(0
.0
3)
13
1.
45
(5
1.
42
)
20
6.
59
(7
0.
45
)
25
5.
76
(9
7.
24
)
22
3.
83
(7
0.
26
)
Y
ea
r
3
C
EA
te
st
s
0.
14
(0
.0
3)
1.
61
(0
.0
6)
0.
02
(0
.0
1)
1.
54
(0
.0
6)
1.
07
(0
.2
1)
12
.0
8
(0
.4
6)
0.
18
(0
.0
9)
11
.5
2
(0
.4
3)
C
T
te
st
s
0.
11
(0
.0
2)
0.
11
(0
.0
2)
0.
76
(0
.0
4)
0.
79
(0
.0
4)
14
.3
3
(2
.7
3)
14
.3
8
(2
.4
4)
99
.6
8
(4
.9
2)
10
3.
02
(5
.1
4)
C
ol
on
os
co
py
0.
07
(0
.0
1)
0.
04
(0
.0
1)
0.
11
(0
.0
2)
0.
11
(0
.0
2)
35
.8
6
(7
.5
6)
20
.5
6
(5
.8
2)
55
.0
1
(9
.2
0)
57
.8
7
(9
.9
7)
Ra
di
og
ra
ph
y
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
04
(0
.0
1)
0.
06
(0
.0
2)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
1.
61
(0
.5
6)
2.
25
(0
.6
8)
M
RI
sc
an
s
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
63
(0
.6
3)
Su
rg
er
y
2
(0
.6
6%
)
5
(1
.6
7%
)
1
(0
.3
3%
)
5
(1
.6
6%
)
53
.9
6
(3
8.
09
)
13
5.
71
(6
3.
59
)
47
.4
6
(–
)
14
2.
52
(6
4.
04
)
C
he
m
ot
he
ra
py
1
(0
.3
3%
)
4
(1
.3
3%
)
4
(1
.3
4%
)
4
(1
.3
2%
)
15
.0
1
(–
)
15
6.
71
(7
7.
96
)
15
0.
00
(7
4.
88
)
15
5.
67
(7
7.
45
)
Ra
di
ot
he
ra
py
0
(0
.0
0%
)
2
(0
.6
7%
)
3
(1
.0
0%
)
1
(0
.3
3%
)
0.
00
(0
.0
0)
4.
91
(3
.4
7)
4.
93
(3
.4
8)
12
.4
5
(–
)
G
P
vi
si
ts
0.
41
(0
.0
7)
0.
53
(0
.1
1)
0.
42
(0
.0
8)
0.
68
(0
.2
1)
18
.6
3
(3
.2
4)
23
.6
7
(5
.1
4)
18
.9
0
(3
.5
1)
30
.5
5
(9
.6
3)
PN
vi
si
ts
0.
19
(0
.0
4)
1.
77
(0
.0
7)
0.
20
(0
.0
8)
1.
71
(0
.0
7)
2.
61
(0
.4
7)
23
.7
1
(0
.9
7)
2.
73
(1
.0
2)
22
.9
6
(0
.8
7)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
R
es
o
u
rc
e
it
em
M
ea
n
(S
E)
re
so
u
rc
e
u
se
o
r
n
(%
)
re
ce
iv
in
g
re
so
u
rc
e
M
ea
n
co
st
[S
E
(£
)]
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
D
N
vi
si
ts
0.
05
(0
.0
3)
0.
07
(0
.0
4)
0.
03
(0
.0
2)
0.
69
(0
.4
3)
2.
00
(1
.3
6)
2.
70
(1
.5
3)
1.
10
(0
.6
2)
26
.7
6
(1
6.
70
)
SN
vi
si
ts
0.
09
(0
.0
3)
0.
01
(0
.0
1)
0.
06
(0
.0
3)
0.
21
(0
.1
0)
3.
97
(1
.2
5)
0.
34
(0
.3
4)
2.
67
(1
.3
5)
9.
00
(4
.3
7)
O
ut
pa
tie
nt
vi
si
ts
1.
30
(0
.3
1)
1.
04
(0
.1
7)
1.
68
(0
.1
5)
1.
91
(0
.1
6)
18
6.
48
(4
4.
04
)
14
9.
38
(2
5.
19
)
24
1.
86
(2
2.
29
)
27
4.
74
(2
3.
09
)
In
pa
tie
nt
st
ay
s
0.
08
(0
.0
2)
0.
16
(0
.0
6)
0.
17
(0
.1
7)
0.
12
(0
.0
5)
14
3.
74
(4
6.
68
)
21
3.
99
(7
3.
13
)
13
8.
52
(1
28
.8
9)
82
2.
35
(4
14
.0
0)
Y
ea
r
4
C
EA
te
st
s
0.
13
(0
.0
3)
1.
50
(0
.0
6)
0.
03
(0
.0
1)
1.
42
(0
.0
6)
0.
97
(0
.2
0)
11
.2
5
(0
.4
6)
0.
20
(0
.0
9)
10
.6
8
(0
.4
6)
C
T
te
st
s
0.
09
(0
.0
2)
0.
08
(0
.0
2)
0.
70
(0
.0
4)
0.
70
(0
.0
4)
11
.7
3
(2
.2
4)
10
.4
6
(2
.3
9)
91
.8
1
(5
.0
4)
90
.9
0
(4
.8
3)
C
ol
on
os
co
py
0.
06
(0
.0
1)
0.
06
(0
.0
1)
0.
03
(0
.0
1)
0.
04
(0
.0
1)
32
.4
5
(7
.2
2)
30
.8
4
(7
.0
6)
13
.7
5
(4
.8
0)
22
.1
3
(6
.0
1)
Ra
di
og
ra
ph
y
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
04
(0
.0
1)
0.
04
(0
.0
1)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
1.
74
(0
.5
4)
1.
59
(0
.4
9)
M
RI
sc
an
s
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
64
(0
.6
4)
0.
00
(0
.0
0)
Su
rg
er
y
0
(0
.0
0%
)
3
(1
.0
0%
)
4
(1
.3
4%
)
4
(1
.3
2%
)
0.
00
(0
.0
0)
11
8.
84
(7
4.
29
)
11
0.
52
(5
5.
24
)
10
2.
27
(5
1.
02
)
C
he
m
ot
he
ra
py
0
(0
.0
0%
)
5
(1
.6
7%
)
4
(1
.3
4%
)
2
(0
.6
6%
)
0.
00
(0
.0
0)
19
1.
12
(8
5.
01
)
15
7.
23
(7
8.
22
)
77
.8
3
(5
4.
95
)
Ra
di
ot
he
ra
py
1
(0
.3
3%
)
1
(0
.3
3%
)
1
(0
.3
3%
)
2
(0
.6
6%
)
2.
45
(–
)
12
.5
3
(–
)
12
.5
7
(–
)
4.
88
(3
.4
4)
G
P
vi
si
ts
0.
45
(0
.1
0)
0.
31
(0
.0
6)
1.
07
(0
.6
1)
0.
56
(0
.1
4)
20
.0
3
(4
.4
5)
14
.1
3
(2
.9
1)
47
.9
5
(2
7.
63
)
25
.0
9
(6
.4
4)
PN
vi
si
ts
0.
20
(0
.0
4)
1.
76
(0
.0
8)
0.
87
(0
.6
0)
1.
76
(0
.1
1)
2.
66
(0
.5
7)
23
.5
9
(1
.0
9)
11
.6
7
(8
.1
1)
23
.6
2
(1
.4
2)
D
N
vi
si
ts
0.
02
(0
.0
2)
0.
17
(0
.1
1)
0.
22
(0
.1
2)
0.
04
(0
.0
3)
0.
65
(0
.6
5)
6.
50
(4
.3
8)
8.
43
(4
.5
3)
1.
68
(1
.1
6)
SN
vi
si
ts
0.
09
(0
.0
3)
0.
04
(0
.0
2)
0.
05
(0
.0
2)
0.
12
(0
.0
3)
3.
77
(1
.2
7)
1.
58
(0
.8
8)
1.
98
(0
.7
1)
5.
21
(1
.4
2)
O
ut
pa
tie
nt
vi
si
ts
1.
15
(0
.1
9)
1.
17
(0
.2
8)
1.
74
(0
.1
8)
1.
31
(0
.0
9)
16
5.
05
(2
7.
93
)
16
8.
77
(4
0.
61
)
25
1.
11
(2
6.
63
)
18
9.
20
(1
2.
67
)
In
pa
tie
nt
st
ay
s
0.
10
(0
.0
2)
0.
03
(0
.0
1)
0.
04
(0
.0
2)
0.
06
(0
.0
3)
96
.5
6
(2
7.
87
)
34
.2
7
(2
1.
73
)
46
.7
5
(2
0.
84
)
14
3.
26
(9
5.
65
) co
nt
in
ue
d
DOI: 10.3310/hta21320 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 32
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mant et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
71
TA
B
LE
16
M
ea
n
re
so
u
rc
e
u
se
an
d
u
n
d
is
co
u
n
te
d
co
st
s
p
er
p
at
ie
n
t
b
y
tr
ia
l
ar
m
an
d
ye
ar
o
f
fo
llo
w
-u
p
(c
o
n
ti
n
u
ed
)
R
es
o
u
rc
e
it
em
M
ea
n
(S
E)
re
so
u
rc
e
u
se
o
r
n
(%
)
re
ce
iv
in
g
re
so
u
rc
e
M
ea
n
co
st
[S
E
(£
)]
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
M
in
im
u
m
fo
llo
w
-u
p
ar
m
(N
=
30
1)
C
EA
te
st
in
g
-o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
30
0)
C
T-
o
n
ly
fo
llo
w
-u
p
ar
m
(N
=
29
9)
C
EA
te
st
in
g
an
d
C
T
fo
llo
w
-u
p
(N
=
30
2)
Y
ea
r
5
C
EA
te
st
s
0.
08
(0
.0
2)
1.
78
(0
.0
8)
0.
01
(0
.0
0)
1.
68
(0
.0
7)
0.
57
(0
.1
4)
13
.3
5
(0
.5
7)
0.
05
(0
.0
4)
12
.6
2
(0
.5
4)
C
T
te
st
s
0.
11
(0
.0
2)
0.
06
(0
.0
1)
0.
98
(0
.0
5)
1.
09
(0
.0
5)
13
.9
0
(2
.6
3)
7.
41
(1
.8
5)
12
8.
53
(6
.3
9)
14
1.
97
(6
.8
2)
C
ol
on
os
co
py
0.
29
(0
.0
3)
0.
27
(0
.0
3)
0.
31
(0
.0
3)
0.
34
(0
.0
3)
14
6.
86
(1
3.
41
)
13
7.
07
(1
3.
15
)
15
9.
87
(1
3.
78
)
17
3.
60
(1
4.
22
)
Ra
di
og
ra
ph
y
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
05
(0
.0
1)
0.
04
(0
.0
2)
0.
13
(0
.1
3)
0.
00
(0
.0
0)
1.
87
(0
.5
6)
1.
46
(0
.6
0)
M
RI
sc
an
s
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
01
(0
.0
1)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
1.
28
(1
.2
8)
0.
00
(0
.0
0)
Su
rg
er
y
0
(0
.0
0%
)
2
(0
.6
7%
)
4
(1
.3
4%
)
1
(0
.3
3%
)
0.
00
(0
.0
0)
70
.2
4
(5
1.
80
)
17
6.
03
(8
9.
03
)
34
.7
7
(–
)
C
he
m
ot
he
ra
py
1
(0
.3
3%
)
2
(0
.6
7%
)
2
(0
.6
7%
)
2
(0
.6
6%
)
4.
88
(–
)
55
.0
9
(4
2.
24
)
78
.6
2
(5
5.
50
)
77
.8
3
(5
4.
95
)
Ra
di
ot
he
ra
py
0
(0
.0
0%
)
0
(0
.0
0%
)
1
(0
.3
3%
)
0
(0
.0
0%
)
0.
00
(0
.0
0)
0.
00
(0
.0
0)
2.
46
(–
)
0.
00
(0
.0
0)
G
P
vi
si
ts
0.
43
(0
.1
4)
0.
31
(0
.0
7)
0.
45
(0
.1
4)
0.
53
(0
.1
6)
19
.2
3
(6
.3
4)
14
.1
6
(3
.0
8)
20
.2
6
(6
.1
8)
23
.7
8
(7
.2
0)
PN
vi
si
ts
0.
17
(0
.0
3)
2.
05
(0
.0
9)
0.
14
(0
.0
7)
1.
80
(0
.0
8)
2.
22
(0
.4
2)
27
.5
2
(1
.1
8)
1.
89
(0
.9
5)
24
.1
5
(1
.0
3)
D
N
vi
si
ts
0.
00
(0
.0
0)
0.
05
(0
.0
3)
0.
00
(0
.0
0)
0.
26
(0
.1
8)
0.
00
(0
.0
0)
1.
92
(1
.0
4)
0.
00
(0
.0
0)
10
.2
8
(7
.1
1)
SN
vi
si
ts
0.
06
(0
.0
2)
0.
04
(0
.0
2)
0.
10
(0
.0
2)
0.
05
(0
.0
2)
2.
46
(1
.0
4)
1.
86
(0
.6
9)
4.
37
(1
.0
6)
2.
25
(0
.7
3)
O
ut
pa
tie
nt
vi
si
ts
0.
99
(0
.1
4)
0.
98
(0
.1
4)
1.
64
(0
.0
8)
1.
92
(0
.1
1)
14
2.
56
(2
0.
38
)
14
1.
12
(1
9.
62
)
23
6.
37
(1
0.
93
)
27
6.
94
(1
6.
27
)
In
pa
tie
nt
st
ay
s
0.
02
(0
.0
1)
0.
05
(0
.0
2)
0.
08
(0
.0
2)
0.
05
(0
.0
2)
37
.3
5
(1
8.
34
)
66
.3
2
(3
3.
93
)
73
.2
2
(2
6.
80
)
10
8.
49
(4
1.
40
)
D
N
,
di
st
ric
t
nu
rs
e;
PN
,
pr
ac
tic
e
nu
rs
e;
SN
,
st
om
a
nu
rs
e.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
TABLE 17 Proportion of surviving patients reporting some or severe problems on each domain of the EQ-5D,
by year and arm
EQ-5D domain Minimum follow-up CEA testing only CT only CEA testing and CT
Mobility
Baseline 0.24 0.23 0.23 0.28
1 0.26 0.22 0.27 0.26
2 0.30 0.27 0.25 0.24
3 0.27 0.28 0.23 0.27
4 0.27 0.30 0.25 0.27
5 0.27 0.27 0.24 0.35
Self-care
Baseline 0.07 0.05 0.06 0.07
1 0.06 0.05 0.07 0.05
2 0.07 0.06 0.06 0.06
3 0.05 0.08 0.06 0.09
4 0.05 0.04 0.05 0.07
5 0.06 0.07 0.06 0.10
Usual activities
Baseline 0.32 0.33 0.33 0.39
1 0.29 0.24 0.28 0.24
2 0.33 0.24 0.26 0.25
3 0.29 0.33 0.22 0.28
4 0.24 0.30 0.29 0.27
5 0.30 0.26 0.24 0.32
Pain/discomfort
Baseline 0.38 0.39 0.35 0.38
1 0.29 0.31 0.28 0.33
2 0.36 0.29 0.23 0.34
3 0.35 0.35 0.26 0.31
4 0.35 0.34 0.30 0.35
5 0.34 0.26 0.23 0.35
Anxiety/depression
Baseline 0.25 0.25 0.25 0.24
1 0.24 0.26 0.25 0.23
2 0.29 0.23 0.29 0.26
3 0.31 0.23 0.28 0.25
4 0.26 0.22 0.25 0.26
5 0.28 0.21 0.25 0.27
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Appendix 4 Quality-of-life questionnaire
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UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
Health Questionnaire
English version for the UK
(Validated for Ireland)
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UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
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Sa
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le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
0
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today.
Best imaginable 
health state
Worst imaginable 
health state
Your own health 
state today
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Section 3  
 
 
 
 
1.    I feel tense or "wound up": 
Most of the time         
   
A lot of the time 
From time to time, occasionally 
Not at all
 
2.    I still enjoy the things I used to enjoy: 
Definitely as much         
Not quite so much 
Only a little 
Hardly at all 
 
3.    I get a sort of frightened feeling as if something awful is about  
to happen: 
Very definitely and quite badly
Yes, but no too badly  
A little, but it doesn't worry me 
Not at all 
 
4.    I can laugh and see the funny side of things: 
As much as I always could        
Not quite so much now 
Definitely not so much now 
Not at all 
5.    Worrying thoughts go through my mind: 
A great deal of the time        
A lot of the time 
From time to time, but not too often 
Only occasionally 
 
6.    I feel cheerful: 
Not at all          
Not often 
Sometimes
Most of the time 
 
7.    I can sit at ease and feel relaxed: 
Definitely          
Usually 
Not often 
Not at all      
Please tick one box per question to describe how you feel 
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8.    I feel as if I am slowed down: 
Nearly all the time         
Very often 
Sometimes 
Not at all 
 
9.    I get a sort of frightened feeling like "butterflies" in the stomach: 
Not at all          
Occasionally  
Quite often 
Very often 
 
10.  I have lost interest in my appearance: 
Definitely          
I don't take as much care as I should  
I may not take quite as much care 
I take just as much care as ever 
 
11.  I feel restless as I have to be on the move: 
Very much indeed         
Quite a lot 
No very much 
Not at all 
 
12.  I look forward with enjoyment to things: 
As much as I ever did         
Rather less than I used to 
Definitely less than I used to   
Not at all 
 
13.  I get sudden feelings of panic: 
Very often indeed 
Quite often 
Not very often 
Not at all 
 
14.  I can enjoy a good book or radio or TV programme: 
Often           
Sometimes 
Not often 
Very seldom 
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Section 4        Your use of Health Services 
 
We would be grateful if you answer these questions about your use of health services 
over the last  
12 months for reasons related to bowel cancer.  If you are not sure, please give us 
your best guess. 
 
1. Over the last 12 months, how many times you have visited or been visited by 
the  following for  reasons related to bowel cancer. 
 
 GP:    ………………………... ……….                  District/community 
nurse at home:  ................... 
  
 Practice nurse:  ……………………….                Stoma nurse: 
……………………………………... 
  
 An out-patient clinic:  ………………… 
 
 
2. Over the last 12 months, have you had any overnight stays in hospital for 
reasons related to  bowel cancer?   (please tick as appropriate) 
  
  Yes:          No:        
 
 If yes, number of hospital stays:  …………………………… 
 
 If yes, total number of nights in hospital:  …………………. 
 
 
3. Over the last 12 months, has your home required any adaptations or aids such 
as bath lifts or  hoists, for reasons related to bowel cancer?    (please tick as 
appropriate) 
 
  Yes:        No:         
 
 If yes, please give details here:  
……………………………………………………………………….. 
 
 
4.  Over the last 12 months, have you relied on family or friends to provide 
regular care to you for  reasons related to bowel cancer?   (please tick as 
appropriate) 
 
  No:                     Yes, less than an hour a day:                   Yes, more than an 
hour a day:   
 
 
5.  Are you currently in paid employment?  (please tick as appropriate) 
 
  No:                                           Yes, full time:                                              Yes,  
part-time:  
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6.  Over the last 12 months, have reasons related to bowel cancer made you: 
 
  reduce your weekly working hours?     No:                       Yes, by: 
…………….. hours per week  
  reduce your other normal activities?      No:                        Yes, by: 
……………..hours per week 
 
 
7.  If you would like to tell us about any other costs you have incurred over the 
last 12  months for  reasons related to bowel cancer, please write them here: 
 
 
 
Thank you very much for taking the time to complete this questionnaire! 
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Appendix 5 Patient and public involvement
The FACS trial had a patient and public involvement (PPI) member actively engaged in the developmentand planning of the trial. Having strong involvement in bowel cancer campaigns and patient groups,
the PPI member was ideally placed to offer a patient voice to the trial and was a full member of the
trial management group. Alongside this, the FACS trial was in the National Cancer Research Institute
Colorectal Clinical Studies Group portfolio and was regularly discussed by the group, which included
PPI representation.
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